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The physiological link between circulating high density lipoprotein (HDL) levels and
cardiovascular disease is well-documented, albeit its intricacies are not well-understood.
An improved appreciation of HDL function and overall role in vascular health and disease
requires at its foundation a better understanding of the lipoprotein’s molecular structure,
its formation, and its process of maturation through interactions with various plasma
enzymes and cell receptors that intervene along the pathway of reverse cholesterol
transport. This review focuses on summarizing recent developments in the field of
lipid free apoA-I and HDL structure, with emphasis on new insights revealed by
newly published nascent and spherical HDL models constructed by combining low
resolution structures obtained from small angle neutron scattering (SANS) with contrast
variation and geometrical constraints derived from hydrogen–deuterium exchange (HDX),
crosslinking mass spectrometry, electron microscopy, Förster resonance energy transfer,
and electron spin resonance. Recently published low resolution structures of nascent
and spherical HDL obtained from SANS with contrast variation and isotopic labeling
of apolipoprotein A-I (apoA-I) will be critically reviewed and discussed in terms of how
they accommodate existing biophysical structural data from alternative approaches.
The new low resolution structures revealed and also provided some answers to long
standing questions concerning lipid organization and particle maturation of lipoproteins.
The review will discuss the merits of newly proposed SANS based all atom models for
nascent and spherical HDL, and compare them with accepted models. Finally, naturally
occurring and bioengineered mutations in apoA-I, and their impact on HDL phenotype,
are reviewed and discuss together with new therapeutics employed for restoring HDL
function.
Keywords: apolipoprotein A-I (apoA-I), high density lipoprotein (HDL), hydrogen–deuterium exchange mass
spectrometry (HDX-MS), small angle neutron scattering (SANS) with contrast variation, electron paramagnetic
spectroscopy (EPR), Förster resonance energy transfer (FRET), electron microscopy (EM), molecular dynamics
(MD) simulation
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INTRODUCTION
Decades of research have confirmed that high density lipoprotein
(HDL), a plasma cholesterol carrier, is anti-atherogenic and anti-
inflammatory in its native state, however it gains atherogenic
and pro-inflammatory properties when it becomes dysfunctional
via systemic and vascular inflammation (Rosenson et al., 2016).
Also, HDL is anti-apoptotic, shields lipids from oxidation, and
recovers endothelial function, features that allow HDL to retard
atherosclerosis.
While several studies initiated the debate on how strongly
plasma HDL levels correlate with cardiovascular disease (CAD;
Vergeer et al., 2010), recent advances in understanding the
structure of HDL and its multiple physiological functions
suggest that chemical modifications of its main protein
component, apolipoprotein A-I (apoA-I) by oxidative/nitrating
agents generated by myeloperoxidase (MPO), are to a great
extend responsible for loss of function and the accumulation
of dysfunctional heavily oxidized and crosslinked apoA-I in the
artery wall (Smith, 2010; DiDonato et al., 2013, 2014; Huang et al.,
2013, 2014; Rosenson et al., 2016). Investigating the susceptibility
of apoA-I to oxidative damage at sites of inflammation can help
understand how dysfunctional HDL emerges (DiDonato et al.,
2013, 2014; Huang et al., 2013, 2014), and should lead to better
ways to shield apoA-I from chemical alteration, and to efficient
therapeutic approaches for treating atherosclerosis. Overall, the
normal physiological activity of HDL rendered dysfunctional,
can be resurrected to some extent by therapies with statins and
niacin (Lüscher et al., 2014; Rosenson et al., 2016).
Finally, understanding apoA-I oxidative damage requires
detailed knowledge of its tertiary structure in both lipid-free and
lipid-bound (HDL) forms, and of the remodeling events an HDL
particle experiences in its journey from the formation of nascent
HDL (nHDL), through the ABCA1 receptor, to the delivery of
cholesterol to liver for catabolism and excretion.
This review is not intended to be a comprehensive
presentation of published experimental and theoretical
studies about the structure and function of HDL. For such
information the reader is directed to reviews by Brouillette and
Anantharamaiah (1995), Thomas et al. (2008), Phillips et al.
(Lund-Katz and Phillips, 2010; Phillips, 2013), and Rosenson
et al. (2016) Rather, this paper focuses on reviewing recently
published experimental data and theoretical models of lipid free
apoA-I and low resolution structures of nHDL and spherical
HDL (sHDL) obtained from SANS with contrast variation and
isotopic labeling of apoA-I. Changes in HDL phenotype and
function upon various naturally occurring and bioengineered
mutations in apoA-I, and posttranslational modifications are
also reviewed. This review ultimately attempts to evaluate
critically how theoretical models of lipid free apoA-I constructed
by computational protocols, and HDL models derived from
SANS with contrast variation accommodate existing biophysical
structural data from alternative approaches.
MODELS OF LIPID FREE apoA-I
Human apoA-I, a 243 amino acid residue amphipathic protein
expressed in liver and intestine (Tall, 1998), binds phospholipids
(PL), and free cholesterol (FC) from cell membrane in a
process mediated by the ATPase cell receptor ABCA1 (Brunham
et al., 2006; Zannis et al., 2006). The first 43 amino acids of
the protein primary sequence are encoded by exon three in
the apoA-I gene, while exon four encodes the remainder of the
primary sequence consisting of 11 and 22 residue repeats (often
separated by proline) with amino acid distribution characteristic
to an amphipathic α-helix (Segrest, 1977). ApoA-I, the major
protein constituent of HDL, is a scaffold for packing lipids
(PL, FC, cholesterol ester (CE), triglycerides (TG)); the protein
provides thermodynamic stability and physiological functionality
to HDL particles in various stages of maturation. Unraveling
and understanding the molecular details of its highly dynamic
structure is still a challenge and remains a focus for lipoprotein
research (Phillips, 2013).
The interaction of lipid-free apoA-I with ABCA1 initiates
the translocation of excess FC from periphery cells to liver
(the reverse cholesterol transport: RCT). Hence, there is great
interest in understanding the molecular details of various steps
in RCT like apoA-I/ABCA1 interaction, apoA-I lipidation and
dimerization, formation of nHDL and sHDL, HDL binding to
the SR-BI receptor, and so forth. For example, the mechanism
through which lipid-free apoA-I self-associates in antiparallel
fashion within the HDL particle is still unknown. Is the apoA-
I monomer or an apoA-I dimer the relevant molecular state for
the interaction with ABCA1 or with the cellular membrane? Do
apoA-I chains associate in an antiparallel orientation before or
after lipidation? A better understanding of the structure and the
dynamics of the full length lipid-free apoA-I in solution is needed
to answer these questions.
Circular dichroism (CD) measurements on lipid free apoA-
I show that about half of the protein chain is in α-helical
conformation (Davidson et al., 1996; Gursky and Atkinson, 1996;
Saito et al., 2003; Silva et al., 2005a; Jayaraman et al., 2011a).
The CD data agree with hydrogen–deuterium exchange mass
spectrometry (HDX-MS) studies performed on lipid free apoA-
I in solution (Wu et al., 2007; Chetty et al., 2009), which indicate
that most of the N-terminus (Nt) (P7–L44, T54–G65, E70–Y115)
has α-helix conformation while the C-terminus (Ct, E179–Q243)
is in random coil conformation (Chetty et al., 2009).
Thermodynamics of Lipid Free apoA-I
Analytical ultracentrifugationmeasurements indicated that lipid-
free apoA-I in solution is actually a mixture of monomers
packed as a helical bundle or in an elongated helical hairpin
conformation (Rogers et al., 1998a). Gursky et al. (Gursky and
Atkinson, 1996) investigated the thermodynamic stability of lipid
free apoA-I in solution, and the unfolding from lipid free to
lipid bound state by differential scanning calorimetry (DSC).
The authors found that lipid-free apoA-I dynamics in solution
is characterized by a compact folding state that lacks a definite
tertiary structure as would a molten globular state (Freire, 1995,
1997), albeit half of its secondary structure is α-helical (Davidson
et al., 1996; Gursky and Atkinson, 1996; Saito et al., 2003; Silva
et al., 2005a; Jayaraman et al., 2011a). When binding to lipids, the
change in apoA-I conformation is accompanied by an increase in
its structural order (the α-helical content increases ∼15%) in the
same way a native state is more ordered than the molten globular
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state it originated from. The authors of this study suggest that in
plasma, lipid free apoA-I is in a molten globular state when starts
to associate with membrane lipids (Gursky and Atkinson, 1996).
Furthermore, the temperature and enthalpy of melting for
lipid free apoA-I major conformational transition were found to
be independent of concentration; apoA-I is mostly multimeric in
the range of concentrations used in this study (1.7–4.7mg/mL),
suggesting that monomer unfolding is detected in the experiment
rather than multimer dissociation (Gursky and Atkinson, 1996).
This means that hydrophobic interactions between the α-helices
of lipid free apoA-I might not contribute substantially to the
thermodynamic stability of the monomeric state. In conclusion,
the thermodynamic properties of lipid free apoA-I at plasma
concentrations should be typical for a molten globular state,
i.e., the protein has a compact folding, with a core of α-
helices bundled via hydrophobic contacts (Barbeau et al., 1979;
Atkinson and Small, 1986; Nolte and Atkinson, 1992; Gursky
and Atkinson, 1996), a reduced cooperative unfolding (Reynolds,
1976; Gursky and Atkinson, 1996), lacks a defined tertiary
structure, has increased solvent access to its hydrophobic surfaces
(Reynolds, 1976; Rosseneu et al., 1977; Gursky and Atkinson,
1996), is easily denatured, has high affinity for hydrophobic
ligands, and a predisposition to form aggregates (Reynolds, 1976;
Tall et al., 1976).
Biophysical Insights into the Structure of
Lipid Free apoA-I
Many biophysical studies concurred that lipid free apoA-I has the
ability to easily change conformation and rearrange and exchange
when interacting with lipids (Narayanaswami and Ryan, 2000),
but at the same time the intrinsic high mobility of certain apoA-
I domains (Nt and Ct termini) hampered any crystallization
attempts for either the lipid free or lipid bound forms. To gain
insight into apoA-I structure, researchers looked for investigative
tools that can gauge to some extent apoA-I’s plasticity and the
conformational diversity that accompany the transition from
lipid free to lipid bound. Earlier studies on apoA-I structure
using monoclonal antibodies (Collet et al., 1991; Marcel et al.,
1991; Calabresi et al., 1993), 13C NMR (Sparks et al., 1992a), and
fluorescence spectroscopy (Jonas et al., 1990) revealed that the
Nt is flexible and changes conformation when apoA-I associates
with lipids (Marcel et al., 1991; Sparks et al., 1992a,b; Meng et al.,
1993).
However, limitations in the experimental techniques used
initially resulted in the characterization of Nt of different lengths,
which made it difficult to ascertain the role of various apoA-
I domains to protein function. For example, the fluorescence
experiments produced data about the entire D1–W108 domain
because all tryptophan residues are located in this region and
the spectroscopic method cannot assign signals to individual
tryptophan residues (Jonas et al., 1990). In another type of
analysis, proteolysis studies indicated that an even larger lipid
free apoA-I Nt domain (D1–Y115) is resistant to protease
cleavage (Brouillette and Anantharamaiah, 1995). These studies
concluded that both lipid-free and lipid-bound apoA-I are
cleaved at helices 5 and 6 (P99–S142) while the other helices
remain shielded, suggesting that P99–S142 is a hinged domain
(Brouillette and Anantharamaiah, 1995). In the meantime, other
researchers succeeded on characterizing smaller domains of
the Nt (D1–A15, L14–L90) by employing monoclonal antibodies
that recognize specific apoA-I epitopes (Curtiss and Smith,
1988; Marcel et al., 1991; Bergeron et al., 1995; Curtiss et al.,
2006).
In addition, techniques like, protein denaturing (Gursky and
Atkinson, 1996; Rogers et al., 1997), circular dichroism (CD;
Gursky and Atkinson, 1996; Rogers et al., 1997), surface balance
measurements (Phillips and Krebs, 1986; Ibdah and Phillips,
1988; Rogers et al., 1997), fluorescence spectroscopy (Jonas et al.,
1990), indicated that the apoA-I Nt domain D1–N43 affects
both the stability and the conformation of lipid free apoA-I in
solution, and that the full length apoA-I is more stable, and has
a different conformation than the truncated form (143–apoA-
I). Moreover, it was shown that the domain D1–N43 is better
conserved across different species when compared to Ct (A44–
Q243) and it belongs to a different amphipathic α-helix class (G∗)
than the rest of the protein (class A, Y; Segrest et al., 1992).
Segrest et al. demonstrated that in a class G* amphipathic α-helix
charged residues are distributed randomly on the polar side of the
amphipathic α-helix; in a class A, the positively charged residues
are located at the polar–non-polar interface, while negatively
charged residues aggregate at the center of the polar face; in a class
Y amphipathic α-helix the positively charged residues are found
both at the polar–non-polar interface and at the center of the
polar side (Segrest et al., 1990, 1992, 1994; Jones et al., 1992). In
addition of being a different type of amphipathic α-helix, several
residues in the D1–N43 domain are in random coil conformation
(Marcel et al., 1991; Nolte and Atkinson, 1992; Segrest et al., 1992,
1994), which would suggest different physiological functions for
the Nt and Ct domains of apoA-I.
Crystal Structures of Lipid Free apoA-I
Despite the fact that researchers have been unsuccessful in
crystalizing the full length apoA-I, two crystal structures of
truncated human apoA-I were resolved and published (Borhani
et al., 1997; Mei and Atkinson, 2011). The first crystal structure
published by Borhani et al. (1997; PDB id: 1AV1) corresponds to
an Nt truncated mutant of apoA-I that misses the first 43 amino
acid residues (143–apoA-I). The unit cell (PDB id: 1AV1) shows
a twisted ring tetramer (Figure 1A, left) formed from two apoA-
I dimers with apoA-I chains shielding each other’s hydrophobic
surface by mutual interaction (Figure 1A, right, the sphere
representation of the hydrophobic and hydrophilic surfaces of
143–apoA-I are colored in green and orange, respectively). The
chains in each dimer, colored with gradient red/blue (Nt = solid
color, Ct = faded color), are oriented antiparallel (Figure 1B, left)
such that helix 5 of one monomer (P121–S142) superposes with
helix 5 of the other monomer (helix 5 registry, Figure 1B, right).
The crystal structure has a high α-helical content (∼93%) and
part of Ct, largely hydrophobic (Saito et al., 2004), is α-helical
(S228–T242) and mutually interacts with the same Ct segment
(S228–Q243) of the other chain in the dimer (Figure 1B, left).
The Ct pair of one dimer interacts with helices 5 (P121–S142) of
the other dimer. Proline residues that initiate 11 and 22 residue
repeats along the apoA-I chain are shown as yellow spheres
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FIGURE 1 | Crystal structures of truncated lipid free apoA-I. Both crystal structures have the apoA-I chains orientated antiparallel in helix 5 registry, i.e., the helix
5 domains (P121–S142 ) from both chains are on top of each other. (A) Left: Cartoon representation of the crystal structure of the 143–apoA-I (Nt truncated apoA-I)
tetramer (PDB id: 1AV1). The structure shows two twisted apoA-I dimers (A,B and C,D) mutually interacting through their hydrophobic surfaces created by the protein
chains when in α-helix conformation. The chains in each dimer are colored with gradient red/blue (Nt = solid color and Ct = faded color). Right: sphere representation
of the hydrophobic (green) and hydrophilic (orange) surfaces of the apoA-I tetramer. (B) The crystal structure of the 143–apoA-I (Nt truncated) dimer (PDB id: 1AV1).
Left: Proline residues that initiate 11 and 22 residue repeats are shown as yellow spheres. Right: the hydrophilic/hydrophobic surface of the dimer in sphere
representation. The Ct domains of apoA-I chains have their hydrophobic surface facing outside the closed-loop dimer, while the helix-5 domains have their
hydrophobic surface facing inside the dimer. (C) Left: Cartoon representation of the crystal structure of the Ct truncated form of lipid free apoA-I (1–185; PDB id:
3R2P). The Nt is shown to fold back and interact with the rest of the chain. Right: the hydrophilic/hydrophobic surface of the dimer is color coded with green/orange,
respectively. The Nt domains of apoA-I chains have their hydrophobic surface facing toward the central region of the dimer, while the helix-5 domains have their
hydrophobic surfaces facing each other.
(Figure 1B, left). The Ct domains of apoA-I chains have their
hydrophobic surface facing outside the ring dimer (Figure 1B,
right), while the helix-5 domains have their hydrophobic surface
facing inside the ring dimer.
Mei and Atkinson (2011) published a second crystal structure
corresponding to an apoA-I Ct mutant having residues G185–
Q243 deleted (1185–243–apoA-I). This crystal structure shows
a dimeric apoA-I with chains oriented antiparallel, in which Nt
folds back to shield part of the hydrophobic surface of the chain
(Figure 1C). Like the 143–apoA-I mutant, the α-helical content
of the Ct mutant (80%) is higher than what the CD (Davidson
et al., 1996; Saito et al., 2003; Silva et al., 2005a; Jayaraman
et al., 2011a) and HDX data (Chetty et al., 2009) for the full
length lipid-free apoA-I indicate (∼55%). Figure 1C, left shows
the cartoon representation of the Ct truncated lipid free apoA-
I, while the right side displays the hydrophobic and hydrophilic
surfaces of the dimer in sphere representation colored with green
and orange, respectively. It is interesting to note that the helix-5
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domains (P121–S142), which are not shielded by Nt from solvent
exposure, have their hydrophobic residues pointing toward each
other (Figure 1C, right), a conformation uncharacteristic for
apoA-I in HDL.
Theoretical Models of Lipid Free apoA-I
The lack of a high resolution crystal structure for the full
length protein and the need to understand apoA-I physiological
properties like cholesterol eﬄux, HDLmaturation, lipid exchange
with cell receptors, etc., stimulated the development of all atom
theoretical models for lipid free apoA-I in solution (Figure 2),
constructed by incorporating many of the biophysical data
gathered from monoclonal antibody, calorimetry (DSC), and
limited proteolysis studies, and various geometrical constraints
derived from 13C NMR, MS-crosslinks, spin coupling (EPR),
FRET, and HDX (Jonas et al., 1990; Collet et al., 1991; Marcel
et al., 1991; Sparks et al., 1992a; Calabresi et al., 1993; Tricerri
et al., 2001; Silva et al., 2005b; Chetty et al., 2009; Jones et al.,
2010; Lagerstedt et al., 2012; Pollard et al., 2013). A huge
amount of research on lipid free apoA-I was carried out and
published in seventies, eighties, and nineties, and there are many
publications reviewing them (Brouillette and Anantharamaiah,
1995), however, this review focuses on the presentation in some
detail of theoretical models of lipid free apoA-I published in the
last decade.
More recent molecular models of lipid free apoA-I were
proposed by Silva et al. (2005b), Lagerstedt et al. (2012),
Pollard et al. (2013), and Segrest et al. (2014; Figure 2). The
molecular models for lipid free apoA-I shown in Figure 2 have
the monomeric protein packed as amphipathic α-helices bundled
together by hydrophobic interactions (Silva et al., 2005b; Pollard
et al., 2013; Segrest et al., 2014). While the three models differ
from each other in the location of α-helices along the apoA-I
chain, they all comply with various sets of MS-crosslinks. Silva
et al. model (Figure 2A, left) was further refined by optimizing
its 3-dimensional geometry through energy minimization (Silva
et al., 2005b), while Segrest et al. (2014) used molecular dynamics
(MD) simulations to validate the thermodynamic stability of their
model (Figure 2C, left, vide infra). It is worth noting that all three
models have part of the Ct domain in α-helical conformation,
which seems to contradict the protein dynamics data for this
region of monomeric lipid free apoA-I (obtained from the HDX-
MS experiment; Chetty et al., 2009) that imply a random coil
conformation for the Ct domain.
Lagerstedt et al. (2012) published the “beta clasp” model of
lipid-free apoA-I that incorporates HDX data (Chetty et al.,
2009), MS-crosslinks (Silva et al., 2005b), and EPRmeasurements
(Lagerstedt et al., 2012). Interestingly, this is the only molecular
model of lipid free apoA-I that has several domains of apoA-
I (Nt, middle domain, and Ct) in β-strand conformation. The
authors suggested that the β-strands might form a hydrophobic
core that stabilizes the amphipathic α-helices when the protein
is free of lipids and self-associated in solution. The authors
hypothesized that the β-strand domains transition to α-helix
when lipids bind to apoA-I. The “beta clasp” model of lipid-
free apoA-I features a loop centered on residue 139 formed by
β-strands pairing. Martin et al. (2006), who identified this loop
FIGURE 2 | Molecular models of lipid free apoA-I. Models of lipid free
apoA-I monomer in solution were proposed over the last decade by Silva et al.
(2005a), Pollard et al. (2013), and Segrest et al. (2014). (A) Left: cartoon
representation of the lipid free apoA-I monomer model proposed by Silva et al.
(2005a). The protein chain is colored with gradient red (Nt is colored with solid
color and Ct with faded color). Right: cartoon representation of a model of a
lipid free apoA-I dimer constructed here by positioning two Silva et al. apoA-I
monomer models next to each other such that the Ct domains of the two
apoA-I chains mutually interact. Most of the reported crosslinks, detected by
MS, are between 15 and 35 Å and located at the interaction interface between
the two monomers in this model of the dimer. (B) Left: cartoon representation
of the lipid free apoA-I monomer model proposed by Pollard et al. (2013).
Right: cartoon representation of a model of lipid free apoA-I dimer built here
from two Pollard et al. apoA-I monomer models. The Ct domains of the two
apoA-I monomers mutually interact and are oriented perpendicular to each
other. The K88–K118 crosslink detected by MS for the apoA-I dimer is about
10 Å in this dimer model. (C) Left: cartoon representation of the lipid free
apoA-I monomer model proposed by Segrest et al. (2014). Right: cartoon
representation of a model of a lipid free apoA-I dimer constructed here by
positioning two Segrest et al. apoA-I monomer models next to each other
such that the Ct domains of the two apoA-I chains are oriented antiparallel and
mutually interact. The K88–K118 crosslink for apoA-I dimer reported by Pollard
et al. (2013) is 58 Å in the dimer model.
domain in nHDL (the “looped-belt” model of nHDL (Martin
et al., 2006), vide infra), claimed that the loop is a key structural
feature of apoA-I.
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More recently, Segrest et al. (2014) proposed a model for
the full length lipid free apoA-I by combining apoA-I domains
from the crystal structures of lipid free apoA-I mutants: 143–
apoA-I (Nt truncated; Borhani et al., 1997) and 1185–243–
apoA-I (Ct truncated; Mei and Atkinson, 2011), followed by MD
simulation on the resultant hybrid model (Segrest et al., 2014).
The conditions for the MD simulations were: NPT ensemble, 1
atm (Berendsen’s pressure bath), the system was preheated for 50
ps and the simulation was carried out for 30 ns at 500 K. Ewald
summation (PME) was used for long range electrostatics and a
12 Å cutoff was employed for van der Waals interactions. The
resulting model of lipid free apoA-I was shown by the authors
to comply with distant constraints derived from EPR (Lagerstedt
et al., 2012), and additional MS-crosslinks identified in the same
study (Segrest et al., 2014).
The CD data show that the α-helical content of lipid
free apoA-I increases when apoA-I forms multimers at higher
concentration (Brouillette and Anantharamaiah, 1995; Gursky
and Atkinson, 1996; Jayaraman et al., 2011a) or when apoA-
I is bound to lipids, which seems to support the idea that
some domain of Ct adopts an α-helical conformation when
interacting with lipids or when apoA-I self-associates (Phillips,
2013). To distinguish between intra- and inter-chain crosslinks,
Silva et al. separated the cross-linked lipid free apoA-I dimer
from themonomer by size exclusion chromatography (Silva et al.,
2005b). The crosslinks originating from the dimer alone are listed
in Table 1 together with distances between the corresponding
amino acid residues measured in the models of lipid free apoA-
I dimers proposed here (vide infra). Table 1 also includes two
crosslinks detected by Pollard et al. (2013) in samples of 1mg/mL,
but not in samples of 0.2mg/mL apoA-I.
By comparing the crosslinking patterns observed in lipid free
apoA-I dimer on the one hand, and nHDL, on the other hand,
Silva et al. concluded that apoA-I in the lipid free dimer is
packed similarly to the lipid free apoA-I monomer and not in
an antiparallel fashion as found in nHDL (Silva et al., 2005b). A
couple of years later, Lagerstedt et al. (2012) proposed the first
molecular model of a lipid free apoA-I dimer based on the “beta-
clasp” model of the lipid free apoA-I monomer (vide supra). In
this apoA-I dimer the apoA-I monomers are aligned according
to the location of the spin coupled residues detected by EPR
(Lagerstedt et al., 2012) and interact mutually through β-strands
domains that mimic the hydrophobic core of nHDL.
To further explore the validity of the lipid free apoA-
I monomer models (Silva et al., 2005b; Pollard et al., 2013;
Segrest et al., 2014) shown in Figure 2 for the purpose of
this review only, models of lipid free apoA-I dimers were
constructed by positioning these monomers with respect to
each other (Figure 2) such that the reported inter-chain MS-
crosslinks (Table 1) are satisfied and the Ct of the two apoA-
I chains mutually interact. Figure 2A, left shows the model of
monomeric lipid free apoA-I proposed by Silva et al. (2005b);
the protein chain is colored with gradient red (Nt = solid
color, Ct = faded color). The right panel of Figure 2A shows a
cartoon representation of a hypothetical lipid free apoA-I dimer
in which most of the reported inter-chain crosslinks (Table 1) are
in range 15–35 Å and located at the interaction interface between
TABLE 1 | MS-crosslinks identified in the lipid free apoA-I dimer, and
Lys-Lys distances, corresponding to these MS-crosslinks, measured in
the model of lipid free apoA-I dimer.
MS-xlinka Silva et al.b Pollard et al.c Segrest et al.d
Observede Distancef Observed Distance Observed Distance
[Å] [Å] [Å]
Nt–Nt
√
22.4 58.9 12.7
Nt–K77
√
48.1 31.5 39.2
50.0 31.0 38.1
Nt–K
g
118 22.6
√
52.5 42.3
24.9 50.8 44.5
Nt–K238
√
16.2 46.7 13.5
18.0 46.2 17.0
K88–K
g
118 45.0
√
12.0 55.8
47.6 9.5 57.0
K208–K208
√
33.2 36.0 46.1
K208–K238
√
29.9 47.1 10.7
31.2 46.0 15.3
K226–K238
√
29.4 29.4 12.0
30.1 28.1 13.7
K238–K238
√
34.8 31.8 29.9
aAmino acid residues forming the crosslink.
bLipid free apoA-I dimer built from Silva et al. lipid free apoA-I monomer model (Silva et al.,
2005a).
cLipid free apoA-I dimer built from Pollard et al. lipid free apoA-I monomer model (Pollard
et al., 2013).
dLipid free apoA-I dimer built from Segrest et al. lipid free apoA-I monomer model (Segrest
et al., 2014).
eThe crosslink is checked if it was experimentally observed in the study that reports the
model for the lipid free apoA-I monomer.
fMinimum distance between the residues involved in the crosslink measured in the lipid
free apoA-I dimer model.
gThis crosslink was reported for an apoA-I concentration of 1 mg/mL but not at 0.2
mg/mL, so it is assumed to form between different apoA-I chains within multimeric lipid
free apoA-I (Pollard et al., 2013).
the two monomers. Figure 2B, left panel shows the cartoon
representation of the lipid free apoA-I monomer model proposed
by Pollard et al. (2013), and amodel of the lipid free apoA-I dimer
is shown in the right panel. The mutually interacting Ct of the
apoA-I chains are oriented perpendicular to each other such that
the crosslink K88–K118 reported for 1 mg/mL apoA-I is satisfied.
The distance between residues K88 and K118 is about 10 Å in
this dimer model, but most of the inter-chain crosslinks reported
by Silva et al. (2005b; Table 1) are not satisfied in this dimer
model. Finally, the left panel of Figure 2C shows the cartoon
representation of the lipid free apoA-I monomer model proposed
by Segrest et al. (2014) and a model of a lipid free apoA-I dimer
at the right. While Segrest et al. (2014) do not specifically report
inter-chain crosslinks, to compare this dimer model with the
dimer models shown in Figures 2A,B, distances corresponding
to the inter-chain crosslinks were measured and listed in Table 1
for this model, too. Many of these inter-chain crosslinks are
satisfied in this apoA-I dimer model making it somewhat similar
to the dimer model from Figure 2A.
In the apoA-I dimer models shown in Figures 2A,C the
inter-chain crosslinks listed in Table 1 are reasonably satisfied,
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except for the one between residues K88 and K118 which has a
distance in the range 45–57 Å. This crosslink, reported by Pollard
et al. (2013) for 1 mg/mL apoA-I, might actually come from
a lipid free full length apoA-I tetramer; in a lipid free apoA-I
tetramer model (Figure 3) built from two identical apoA-I dimer
models (Figure 2C) the distance between residues K88 and K118
from mutually interacting apoA-I chains (belonging to different
dimers) is about 10 Å. Figure 3 displays a cartoon representation
of a lipid free apoA-I tetramer model; the protein chains (A,
B, C, and D) are colored with gradient red/blue/cyan/magenta,
respectively (Nt = solid color, Ct = faded color). The distances
corresponding to the inter-chain crosslink K88–K118 are between
residues K88D and K118A (K88A and K118D) from mutually
interacting apoA-I chains D and A belonging to dimers C/D
and A/B, respectively. This hypothesis regarding the origin of
crosslink K88–K118 reported for 1 mg/mL apoA-I by Pollard
et al. (2013) is supported by the observation made by Silva
et al. (2005b) that lipid free apoA-I contains multimers at
concentrations as low as 0.1mg/mL apoA-I.
MODELS OF NASCENT HDL
The production of nascent HDL (nHDL) from lipid free/lipid
poor apoA-I and cell membrane lipids (PL and FC) by the
ABCA1 receptor is the first step in the reverse cholesterol
transport (RCT; Zannis et al., 2006). Elucidating the RCT
cycle necessitates deep understanding of nHDL structure,
unfortunately, the intrinsic highly dynamic nature of apoA-
I and difficulties in obtaining homogenous HDL preparations
from plasma made the unraveling of defining structural features
of nHDL challenging (Thomas et al., 2008; Phillips, 2013).
Nonetheless, structural studies on nHDL were greatly facilitated
by employing nHDL samples reconstituted from lipid free apoA-
I and lipid vesicles (Jonas, 1986). Adsorption of lipid free apoA-I
on vesicle’s surface facilitates the formation of nHDL (Jayaraman
et al., 2011b).
Reconstituted nHDL is still a heterogeneous mixture of
particles with sizes between 7.8 and 12 nm, each particle having
a particular protein/lipid composition that maximizes protein
lipid interaction and ensures thermodynamic stability (Li et al.,
2004). Nascent HDL contains two to four apoA-I chains (or a
mixture of apoA-I and apoA-II; Cheung and Albers, 1984; Gao
et al., 2012) and can accommodate lipid cargos (PL and FC)
of various sizes by changes in apoA-I conformation and/or the
number of protein chains (Li et al., 2004); a nHDL particle larger
than 12 nm is merely formed when more than two apoA-I chains
with additional phospholipids are incorporated into the particle
(Jonas et al., 1989; Li et al., 2004; Silva et al., 2005b; Vedhachalam
et al., 2010).
Many of the early structural studies of nHDL employed
particles reconstituted with dimyristoylphosphatidylcoline
(DMPC, a shorter saturated acyl chain PL, 14:0), due to its ability
to spontaneously form nHDL particles when DMPC vesicles
were mixed with apoA-I (Atkinson et al., 1976; Jonas et al.,
1977; Tall et al., 1977; Pownall et al., 1978; Swaney, 1980; Matz
and Jonas, 1982). Later, the cholate dialysis method (Nichols
et al., 1983; Jonas, 1986) was reported to allow reconstitution
of nHDL with physiologically relevant PL that have longer and
unsaturated acyl chains like palmitoyloleoylphosphatidylcoline
(POPC, 16:0–18:1). Reconstituted nHDL particles of various
sizes were classified and labeled as a function of the number of
apoA-I chains incorporated into the particle and its overall size
(Li et al., 2004).
In conclusion, nHDL particles can have multiple
compositions including a variable number of apoA-I chains,
few lipid types (PL, FC, etc.), and various numbers of lipids per
nHDL particle. While this multi-size particle conundrum was
early recognized (Brouillette and Anantharamaiah, 1995), the
prevalent opinion seemed to be that the double belt model of
FIGURE 3 | Molecular model of lipid free apoA-I tetramer. The figure shows a cartoon representation of a lipid free apoA-I tetramer model constructed from two
models of lipid free apoA-I dimer shown in Figure 2C, right (based on Segrest et al. lipid free apoA-I monomer, Figure 2C, left; Segrest et al., 2014). The protein
chains are colored with gradient red/blue/cyan/magenta (Nt is colored with solid color and Ct with faded color). The K88–K118 MS-crosslink reported by Pollard et al.
(2013) at a concentration of apoA-I of 1mg/mL may come from a tetrameric state of apoA-I. In this hypothetical tetramer model of lipid free apoA-I, the distance
between K88A and K118C is 10.6 Å and between K88C and K118A is 9.6 Å.
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nHDL (vide infra) is sufficient to explain the structural diversity
and functional features of nHDL (Phillips, 2013).
Discoidal Models of nHDL
In this review discoidal nHDL refers to models of nHDL in which
the protein forms a ring. Experimental evidence produced four
decades ago pointed to the fact that nHDL, a macromolecular
assembly of amphipathic proteins (apoA-I, apoA-II) and lipids
(PL, FC) is made of a lipid bilayer disc with its main protein
constituent (apoA-I) located at disc’s perimeter (Tall et al.,
1976, 1977; Wlodawer et al., 1979; Atkinson et al., 1980; Jonas,
1986). But, the dynamic nature of nHDL, posed insurmountable
challenges to crystallization attempts, thus alternative biophysical
and biochemical approaches were used to extract structural
information about nHDL (Brouillette and Anantharamaiah,
1995; Brouillette et al., 2001). These latter studies lead to early
discoidal models of nHDL like the picket fence model (Jonas
et al., 1989; Wald et al., 1990a,b; Nolte and Atkinson, 1992;
Phillips et al., 1997; Figure 4A), the double belt model (Koppaka
et al., 1999; Segrest et al., 1999; Midtgaard et al., 2015; Figure 4B),
the hairpin model (Silva et al., 2005b; Figure 4C), and double belt
loopmodels (Maiorano et al., 2004; Bhat et al., 2005; Martin et al.,
2006; Wu et al., 2007; Figures 4D,E).
In contrast to lipid free apoA-I, in nHDL, apoA-I is mostly
helical; the overall α-helicity of apoA-I was estimated from
CD to be ∼80% (Jonas et al., 1989; Silva et al., 2005b; Wu
et al., 2007). It is worth noting that the 22 and 11 α-helical
amphipathic repeats that span most of apoA-I chain (L44–Q243),
are structurally similar but differ in their capabilities of binding
lipids (Segrest et al., 2000; Brouillette et al., 2001), which suggests
that their contribution to physiological functions of apoA-I (e.g.,
binding to plasma enzymes and cell receptors) might differ (vide
infra). These early theoretical models of nHDL describe the
particle as having a predominantly α-helical amphipathic apoA-I
arranged around the perimeter of a central lipid bilayer with the
protein orientation dictated by biophysical constraints, like the
hydrophobic and hydrophilic properties along α-helical domains
of apoA-I, and geometry constraints between amino acid residues
of apoA-I chains obtained from MS-crosslinking (Bhat et al.,
2005, 2007; Silva et al., 2005b), Förster resonance energy transfer
(FRET; Maiorano et al., 2004), EPR (Martin et al., 2006),
and solvent accessibility and dynamics along the polypeptide
backbone as probed by hydrogen–deuterium exchange (HDX-
MS; Wu et al., 2007; Chetty et al., 2012).
Historically speaking, the picket fence model (Jonas et al.,
1989; Wald et al., 1990a,b; Nolte and Atkinson, 1992; Phillips
et al., 1997) and the double belt model (Borhani et al., 1997;
Rogers et al., 1998b; Koppaka et al., 1999; Segrest et al., 1999;
Midtgaard et al., 2015) of nHDL were proposed more than two
decades ago. The picket fence model was built from a lipid bilayer
with 144 POPC and 12 FC molecules and two apoA-I monomers
(D48–Q243) arranged in head-to-head or head-to-tail dimer
configuration oriented similar to how trans-membrane α-helices
domains are (Figure 4A, i.e., parallel with the PLmolecules in the
bilayer); MD simulations and simulated annealing further refined
the model (Phillips et al., 1997; Sheldahl and Harvey, 1999). The
MD simulation protocol included the use of the CHARMM all
FIGURE 4 | Discoidal models of nHDL. In all models the apoA-I chains are
shown in cartoon representation and colored with gradient red/blue (Nt = solid
color and Ct = faded color). (A) Left: the picket fence model of the apoA-I
dimer (143–apoA-I; Jonas et al., 1989; Wald et al., 1990a,b; Nolte and
Atkinson, 1992; Phillips et al., 1997); the amphipathic apoA-I α-helices are
oriented parallel with the PL molecules. Right: the picket fence model of nHDL
(Phillips et al., 1997). The lipid bilayer is made of 144 POPC and 12 FC
molecules. (B) Left: computational model of the apoA-I dimer (143–apoA-I)
used in the Double Belt model of nHDL proposed by Segrest et al. (1999); the
apoA-I chains are oriented antiparallel and stacked on top of each other in
helix 5 registry. Right: the Double Belt model of nHDL proposed by Segrest
et al. (1999). The lipid bilayer is made of 160 POPC molecules. (C) Left: model
of the apoA-I dimer (143–apoA-I) used in the Hairpin model of nHDL
proposed by Silva et al. (2005b); apoA-I monomers form semicircular hairpins
located at the periphery of the lipid bilayer, which interact through a couple of
residues from repeat 5 and the end domain of Ct (V221–Q243 ). Right: the
(Continued)
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FIGURE 4 | Continued
Hairpin model of nHDL proposed by Silva et al. (2005b). The lipid bilayer is
made of 156 POPC and eight FC molecules. (D) Left: model of the apoA-I
dimer (143–apoA-I) used in the Looped Belt model of nHDL proposed by
Martin et al. (2006); in this model apoA-I features a highly dynamic region
(K133–E146 ) in random coil conformation that extends half of repeat 5 and the
beginning of repeat 6. Right: the Looped Belt model of nHDL proposed by
Martin et al. (2006). The lipid bilayer is made of 160 POPC molecules. (E) Left:
computational model of the full length apoA-I dimer used in the Solar Flare
model of nHDL proposed by Wu et al. (2007). Similarly with apoA-I in other
belt-type models of nHDL, the apoA-I chains in the Solar Flare model are
oriented antiparallel in helix 5 registry. Right: the Solar Flare model of nHDL
proposed by Wu et al. (Wu et al., 2007). The lipid bilayer is formed of 200
POPC and 20 cholesterol (FC) molecules. This model of nHDL shows the Nt of
apoA-I in a globular conformation.
atom force field, the TIP3P model of water, and a 10 Å cutoff for
van der Waals interactions; the system was first heated up slowly
to 500 K and then cooled down fast to 200 K. The picket fence
model was popular initially and supported by attenuated total
reflection infrared spectroscopy (IR) studies (Wald et al., 1990b).
Both the picket fence and the double belt models are consistent
with early small angle neutron scattering (SANS) with contrast
variation measurements (Atkinson et al., 1980) that supported a
bilayer arrangement of the lipid and a circumferential apoA-I.
The publication of the crystal structure of the Nt truncated
lipid free apoA-I (Borhani et al., 1997; Figure 1A) revived
the interest in the double belt model, which incorporated the
newly discovered structure of the antiparallel apoA-I dimer
and a lamellar lipid (160 PL) extracted from a POPC bilayer
thermodynamically stabilized by MD simulations (Heller et al.,
1993). Subsequently, the double belt model quickly captured
renewed interest from many researchers who used a variety
of biophysical approaches to support it (Koppaka et al., 1999;
Maiorano et al., 2004; Bhat et al., 2005, 2007; Silva et al., 2005b;
Martin et al., 2006). The double belt model of nHDL gained
further acceptance as its overall shape was consistent with images
of discoidal nHDL obtained from earlier EM studies that showed
nHDL particles stacking as coins (a.k.a. “discoidal” nHDL; Forte
et al., 1971; Tall et al., 1977), while MD simulations were used
to demonstrate the thermodynamic stability of the model (Klon
et al., 2002; Catte et al., 2006, 2008; Jones et al., 2009; Gu et al.,
2010). Similar images of nHDL were obtained later by cryo-EM
(Zhang et al., 2011; Zhang and Ren, 2012) and atomic force
microscopy measurements (Gan et al., 2015). In the first MD
simulation (1 ns) of the double belt model (Klon et al., 2002)
the protocol included a simulation temperature of 300 K, the
use of CHARMM22 force field for protein and CHARMM24 for
lipids, van der Waals interactions were truncated beyond 10 Å,
a spherical boundary potential was applied to prevent solvation
shell water molecules from leaving the droplet. Over the years
many researchers came to support the double belt model, which
became the entrenched view of nHDL structure (Lund-Katz and
Phillips, 2010; Phillips, 2013).
Figure 4B shows at the left the ring model of the apoA-I dimer
(143–apoA-I) used by Segrest et al. (1999) to build the double
belt model of nHDL. The Nt truncated apoA-I chains (143–
apoA-I; colored with gradient red/blue) are oriented antiparallel
and stacked on top of each other in helix 5 registry. At the
right, the double belt model of nHDL is displayed in which two
truncated apoA-I chains wrap around a lipid bilayer formed from
160 POPCmolecules; the interior hydrophobic surface of apoA-I
ring interacts with the acyl chains of the lipid.
Figure 4C shows an alternative discoidal model of nHDL
proposed by Silva et al. (2005b) in which apoA-I chains are not
mutually associated with each other, but rather form separate
hairpins circumferentially positioned around the lipid bilayer
and interacting with each other through a couple of residues
from helix 5 and the Ct domain, V221–Q243. The hairpin and
the double belt models are practically indistinguishable as far as
geometrical constraints are concerned, but the double belt model
gives nHDL stronger structural integrity as the two apoA-I chains
are interlocked through salt bridges made by residues carrying
opposite charges (Segrest et al., 1999).
While CD experiments confirmed a high degree of α-helicity
(>70%) for apoA-I in nHDL (Jonas et al., 1989), several studies
revealed that certain regions of apoA-I are highly dynamic and
last long enough in random coil conformation to be detected
through biophysical techniques such as EPR and HDX. These
studies lead to a class of discoidalmodels coined the “looped-belt”
models of nHDL (Maiorano et al., 2004; Bhat et al., 2005; Martin
et al., 2006; Wu et al., 2007). For example, Martin et al. (2006)
used EPR to identify a highly dynamic region of apoA-I that
extend half of helix 5 and the beginning of helix 6 (Figure 4D,
K133–E146). Lagerstedt et al. hypothesized recently that this
region of apoA-I (K133–E146) in random coil conformation is
inherited from lipid free apoA-I and may be a key functional
domain of apoA-I (Lagerstedt et al., 2012).
A more recent looped-belt model of nHDL obtained by
incorporating biophysical constraints derived from hydrogen–
deuterium exchange mass spectrometry (HDX-MS) and MS-
crosslinking data is the Solar Flares model (Wu et al., 2007).
Figure 4E shows at the left the full length apoA-I dimer used
in the Solar Flares model. Similarly to apoA-I in the double belt
model, the apoA-I chains in the Solar Flares model are oriented
antiparallel in helix 5 registry and form a ring. The Solar Flares
model of nHDL is shown in the right panel of Figure 4E, in which
the lipid bilayer was built with 200 POPC and 20 FC molecules;
this model of nHDL has 60 lipids more than the double belt
model and represents a physiologically relevant nHDL particle
as cholesterol was added to the lipid phase and lipid free Nt of
apoA-I were attached in globular conformation.
The Solar Flares and the other belt type models of nHDL
(Figures 4B–D) have both similar and distinctive features. First,
all belt type models have two apoA-I chains oriented antiparallel,
in helix 5 registry, and form a ring. Second, their lipid phase is a
rather planar lipid bilayer circumscribed by the protein. Third,
the models accommodate the majority of distance constraints
derived from MS-crosslinking (Segrest et al., 1999; Silva et al.,
2005b; Wu et al., 2007). The distinctive features are: the Solar
Flares model uses the full length apoA-I with the Nt of apoA-I in a
globular conformationwhile the other belt typemodels use theNt
truncated apoA-I (143–apoA-I). In addition, the conformations
of apoA-I chains in the Solar Flares model accommodate
solvent accessibility and dynamics constraints derived from
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HDX-MS data (Wu et al., 2007). Another distinctive and rather
controversial feature (Shih et al., 2008) of the Solar Flares model
is the presence of the Solar Flares domains (L159–A180) predicted
to have random coil conformation with dynamics restricted by
three-way salt-bridges (R160–H162–D168). These apoA-I domains
predicted to bind to lecithin cholesteryl acyltransferase (LCAT),
the enzyme thatmatures nHDL into sHDL (Wu et al., 2007), were
constructed in random coil conformation to accommodate the
HDX-MS data (Wu et al., 2007).
Salt-bridges (R160–H162–D168) in the Solar Flares loops were
observed to form during energy minimization calculations
performed on the model (Wu et al., 2007). Other researchers
used MD simulations to dispute this feature of the Solar Flares
model by showing that the salt bridges collapse after 1 ns (Shih
et al., 2008). In a subsequent study, Gogonea et al. (2010) used
MD simulations to reinforce the idea that the salt bridges in
the Solar Flares regions of apoA-I are persistent, breaking, and
reforming during the simulation (>80 ns; Gogonea et al., 2010).
The MD simulation protocol used in this study included: NVT
ensemble, simulation temperature 300 K, Berendsen thermostat,
Ewald summation (PME), 10 Å cutoff for van der Waals
interactions, GROMOS87 force field, and the SPC water model.
In retrospect, it seems plausible to consider structural features
like salt bridges as transient constructs that dynamically form
and break. While theoretical calculations can lead to artifacts in
molecular configurations due to simplifications in the molecular
mechanics force fields used to describe molecular interactions,
the experimental HDX-MS measurements on nHDL indicate
that the Solar Flare regions of apoA-I retain a random coil
conformation on a time scale of minutes (Wu et al., 2007).
In brief, while inheriting many features of nHDL belt
type models, the Solar Flares model has its own merits. It
is the first all atom (three dimensional) model of nHDL to
use full length apoA-I, includes information about solvent
accessibility and dynamics of apoA-I with near residue resolution
(achieved through computational manipulation of the entire set
of overlapping peptides produced by the HDX/peptide digestion-
MS experiment, Wu et al., 2007), and incorporates a key
functional feature of nHDL, i.e., the location and conformation
of apoA-I domains (Solar Flares regions) that bind LCAT and
facilitate nHDL maturation.
Despite the fact that belt type models of nHDL incorporate
a wealth of biophysical data, share an antiparallel orientation of
two apoA-I chains and an overall planar conformation of the
apoA-I double chain, none of these models is based upon direct
visualization of the shape of apoA-I or the lipid core within nHDL
in solution. Thus, the overall conformation of the apoA-I dimer
within the particle is still debated (Wu et al., 2009; Gogonea et al.,
2010, 2013; Lund-Katz and Phillips, 2010; Phillips, 2013).
Models of nHDL Derived from SANS with
Contrast Variation
The Use of SANS with Contrast Variation in Structural
Biology
Small-angle scattering (SAS), a technique that rely on scattering
X-rays or neutrons off matter in liquid or solid form, was
employed to investigate the structure of biomolecules in solution
for many decades (Guinier, 1938). The neutrons used in SANS
experiments have low energy (with wavelength in the range
of 4–6 Å) and do not alter the conformation of biomolecules
during scattering in contrast to the (high energy) X-rays
employed in SAXS experiments. This particular characteristic
of the neutrons makes them excellent probes for exploring the
structure of macromolecular complexes. Signal averaging due to
molecular rotation in solution, casted SAS as a low-resolution
structural technique in the sense that it does not produce atomic
coordinates, but rather provides information about the size and
the overall shape of a macromolecular system (Neylon, 2008).
Availability of monodisperse samples is crucial for the accurate
interpretation of the scattering data in terms of structural
parameters; therefore sample preparation and assessment of
monodisperity are critically important factors for SAS structural
studies. In early studies only simple structural features, like the
radius of gyration, were derived from SAS data, but, over time,
the analysis of scattering intensity grew in sophistication leading
eventually to computer programs (Svergun et al., 1995) that can
nowadays de-convolute the scattering intensity into a distance
distribution function, P(r) (Svergun, 1992), and use the latter to
reconstruct a low resolution structure of the molecular system
(Svergun, 1999; Svergun and Koch, 2003; Jacques and Trewhella,
2010).
A significant advance in SAS was the development of SANS
with contrast variation, a more sophisticated technique involving
isotopic labeling of biomolecules and the use of D2O to achieve
the contrast. In a SANS with contrast variation experiment a
component (e.g., protein, lipid, DNA, RNA) in a macromolecular
complex is “masked” by changing the D2O-to-H2O ratio in the
buffer until the scattering length density of the latter matches
that of the masked component. This ability to map the position
of individual components in a macromolecular complex in
solution makes SANS a rather unique technique capable of
connecting structural and stoichiometric information of rather
big macromolecular complexes in a way that is difficult to achieve
by other methods.
SANS with contrast variation was very useful in determining
the arrangement of components within a bimolecular complex.
For example, two decades before the crystal structure of the
nucleosome was resolved (Luger et al., 1997), SANS with contrast
variation predicted the structural orientation of the DNA and
protein components within the fundamental unit of chromatin
(Pardon et al., 1975), and correctly located the protein and RNA
subunits within the ribosome in the 30S subunit (Capel et al.,
1987) and 50S subunit (May et al., 1992). In other studies, SANS
with contrast variation was used to investigate the structure
of T-cell surface glycoprotein CD1d1 in complex with β-2
microglobulin (Schiefner et al., 2009), and the protein kinase R (a
key player in the interferon pathway, VanOudenhove et al., 2009)
known to contain three folded regions separated by disordered
linkers (Lemaire et al., 2006). Yet, in another SANS with contrast
variation study of inhibitor binding (Sda, Whitten et al., 2007
and KipI, Jacques et al., 2008) to histidine kinase (KinA, Bacillus
subtilis), a reduction in the size of the KinA dimer and an
apparent enlargement of inhibitor size, due to two inhibitors
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binding on opposite sides of the KinA dimer, were detected. The
study showed that inhibitors of KinA do not bind to the flexible
hinge connecting the catalytic and self-association regions of
KinA (as previously thought; Rowland et al., 2004), but rather
at the base of the KinA self-association domain. The structural
insight obtained from SANS with contrast variation enthused
new mutagenesis studies (Cunningham and Burkholder, 2009)
that revealed both autokinase and phosphotransferase reactions
to be inhibited by KipI and Sda. The SANS prediction of the Sda
binding site on KinA was later confirmed by the crystal structure
of the complex of KinB (a homolog of KinA from Geobacillus
stearothermophilus) with Sda (Bick et al., 2009).
SANS Low Resolution Structures and Models of
nHDL
Before delving into presenting more recent nHDL models
derived from SANS with contrast variation experiments, it may
be useful to recount that in general lipoproteins (macromolecular
assemblies of proteins and lipids) contain molecules with
different neutron scattering properties making them excellent
candidates for structural studies employing SANS with contrast
variation. For example, the protein and the phospholipid heads
scatter neutrons (at zero scattering angle) as buffer solutions
of 42% D2O and ∼30% D2O, respectively (Serdyuk et al.,
2007). On the other hand, the lipid acyl chains are less dense
and have a higher hydrogen content, thus scattering neutrons
as a buffer solution of ∼5% D2O (Serdyuk et al., 2007).
Because a lipid molecule is composed of domains with different
neutron scattering properties (lipid head vs. tail), as a whole, a
phospholipid exhibits neutron scattering properties as a solution
with 12% D2O (Serdyuk et al., 2007).
Nearly four decades ago, Atkinson et al. reported small angle
X-ray scattering (SAXS; Atkinson et al., 1976) and SANS with
contrast variation studies (Atkinson et al., 1980) on nHDL
reconstituted with DMPC. The authors have not published a
low resolution structure of nHDL at that time, but their findings
supported the idea that the shape of nHDL is oblate, the lipid is
bilayer and the protein is circumferential to the lipid within the
particle, and stated that their SAXS and SANS data are consistent
with the discoidal model of nHDL. Additional small angle X-
ray scattering (SAXS) studies on reconstituted nHDL and MD
simulations (Denisov et al., 2004; Shih et al., 2007; Jones et al.,
2009) lent further credence to the discoidal model.
Preliminary SANS experiments on nHDL particles
reconstituted with the wild type protein revealed that the
difference in neutron scattering properties of the protein and the
lipid (42 vs. 12% D2O) is not enough to produce a well-resolved
low resolution structure for the protein (Wu et al., 2009).
To enhance the contrast (difference in scattering properties)
between the protein and the lipid, the protein is labeled through
deuterium enrichment by expressing it in media containing D2O
(Wu et al., 2009). The buffer solution matches the scattering
properties of a deuterium-enriched protein when it has ∼92%
D2O and the contrast between protein and lipid (given in %D2O)
increases from 30 (=42–12) to 80 (=92–12); the scattering
intensity increases with the square of the contrast (Svergun and
Koch, 2003).
The Double Superhelix Model of nHDL
Wu et al. obtained the first low resolution structure of nHDL by
employing SANS with contrast variation and isotopic labeling of
the protein component (Wu et al., 2009). The nHDL particles
used in this study (prepared with the cholate dialysis method
Jonas, 1986) were 11 nm in diameter measured by light scattering
(9.6 nm from ND-PAGE gel), and contained two apoA-I chains,
210 POPC and 15 FC per nHDL particle (Wu et al., 2009); an
nHDL particle with a similar size and composition was reported
by Marcel and coworkers (Calabresi et al., 1993; Meng et al.,
1993). Wu et al. reported low resolution structures both for the
protein and the lipid components of nHDL (Wu et al., 2009),
and the low resolution structure for the protein component,
shown in the left panel of Figure 5A, was obtained from
measurements of nHDL particles reconstituted with deuterium-
enriched apoA-I and dialyzed in a buffer solution with 12%
D2O. At this concentration of D2O the lipid phase and the
buffer have the same scattering properties, so the lipid phase
becomes “transparent” and the difference in scattering signal
(between sample and buffer) is due to the protein alone. The low
resolution structure of apoA-I in this nHDL particle turned out
to be an open spiral (Wu et al., 2009). A second measurement
of nHDL particles reconstituted with non-labeled apoA-I and
dialyzed in a buffer solution with 42% D2O provided the low
resolution structure for the lipid phase of nHDL, which has
an ellipsoidal (prolate) shape (Figure 5A, middle). The low
resolution structure of nHDLwas obtained by combining the low
resolution structures for the protein and the lipid components
(Wu et al., 2009; Figure 5A, right).
Further, the authors used geometrical constraints derived
from other biophysical methods like MS-crosslinking, FRET,
EPR, HDX-MS, particle composition analyses, to build a
molecular model that could fit two full length apoA-I chains
into the low resolution structure of the protein component
(Figure 5B, left), and 200 PL (POPC) and 20 FC molecules into
the low resolution structure of the lipid component (Figure 5B,
middle). The combined low resolution structure of the protein
and lipid was used to determine the orientation of PL and FC
molecules such that the hydrophobic surface of the protein is
in contact with the acyl chains of the lipids. This requirement
together with the open conformation of the protein lead to a lipid
phase model with combined lamellar–micellar arrangement and
not a pure bilayer as in discoidal nHDL. The combinedmolecular
model for the protein and lipid was coined the Double Superhelix
model (DSH); Figure 5B shows at the left the spiral conformation
of the apoA-I double chain, in the middle the overlap between
the all atom model and the low resolution structure of the
protein component, and the DSH all atom model of nHDL at the
right.
TheDSHmodel hasmany common features with the discoidal
models of nHDL, but at the same time has several distinctive
new characteristics. Like the discoidal models of nHDL, the
DSH model incorporates two apoA-I chains per nHDL particle
associated in antiparallel orientation in helix 5 registry. The
two apoA-I chains, made to a large extent of amphipathic α-
helices, define a hydrophobic surface facing and binding the lipid
acyl chains. The DSH model accommodates all MS-crosslinks,
Frontiers in Pharmacology | www.frontiersin.org 11 January 2016 | Volume 6 | Article 318
Gogonea HDL Structure
FIGURE 5 | The low resolution structure and the DSH model of nHDL reconstituted with POPC and FC. (A) Left: The low resolution structure of the protein
component of nHDL. Middle: The low resolution structure of the lipid component of nHDL. Right: The low resolution structure of nHDL as a combination of the low
resolution structures of the protein and lipid components of nHDL. (B) Left: the DSH model of the full length apoA-I dimer in nHDL proposed by Wu et al. (2009). The
apoA-I chains shown in cartoon representation and colored with gradient red/blue, are oriented antiparallel in helix 5 registry. The Solar Flares domains introduced in
the Solar Flares model of discoidal nHDL were retained in this model of nHDL to accommodate the HDX-MS data. Middle: Superposition of the spiral apoA-I double
chain with the low resolution structure of the protein component of nHDL obtained by SANS with contrast variation. Right: The DSH model of nHDL; the lipid model
was built from 200 POPC and 20 FC molecules in a combined micellar/lamellar phase. The lipids in close proximity to protein follow a lamellar arrangement while
those further away are arranged radially (as in a micelle) in order to accommodate the open conformation of apoA-I and avoid exposing acyl chains to solvent.
EPR, and FRET distance constraints reported for nHDL and
confirmed in the double belt and Solar Flares models as well. The
phospholipid molecules are oriented such that their heads are on
particle’s surface while their tails are inside the particle interacting
with one another and with the protein hydrophobic surface. Like
the Solar Flares model, the DSH model was constructed with full
length apoA-I chains.
The most distinctive feature of the DSH model is the open
shape of the apoA-I double chain, whose conformation follows
the experimentally determined low resolution structure of apoA-
I in nHDL (Figure 5B, middle). That is, the protein belt made
of two antiparallel oriented apoA-I chains does not form a ring
as in discoidal models. The open conformation of the protein
implies the existence of regions of the lipid phase, which are not
bilayer but rather monolayer with radial orientation of PL like in
micelles. However, the PL in close proximity to the protein adopts
a bilayer arrangement as in discoidal models because of their
interaction with the protein inner hydrophobic surface and the
requirement that the PL polar head groups remain on the particle
surface. It is important to emphasize that three dimensional
discoidal models are not based on direct visualization of an
nHDL particle, but they are rather computational-theoretical
models that incorporate geometrical constraints derived from
various biophysical techniques (MS-crosslinking, FRET, ESR,
HDX-MS, etc).
Despite its many similarities with the discoidal models
of nHDL, the DSH model was met with resistance and
skepticism. For example, Jones et al. (2010) referred to the
DSH model as “dramatically different from the standard model”
and questioned its validity through the use of MD simulations
(65 ns; Jones et al., 2010) concluding that the DSH model
is not thermodynamically stable. In addition, these authors
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showed by FRET that the distance between residues 40 and
240 of apoA-I in nHDL is in the range of 28–34 Å (Jones
et al., 2010) and cannot be accommodated by the DSH model.
In another computational study of the DSH model (using a
different simulation temperature and ensemble), Gogonea et al.
(2010) used also MD simulation (>80 ns) to investigate the
thermodynamic stability of the DSH model and found that
the model is thermodynamically stable for tens of nanoseconds
(Gogonea et al., 2010), the apoA-I chains retain the open
conformation (spiral shape) and the lipid phase remained a
lamellar–micellar mixture. While the elongated lipid phase
ellipsoid (prolate) changed somewhat into a spheroid, the most
distinctive features of the model were preserved during the
entire simulation. The overall change in the shape of the particle
might be attributed to the simplified molecular mechanics force
fields used to describe molecular interactions in MD simulations
(Gogonea et al., 2010).
In addition, Gogonea et al. (2010) showed that following MD
simulation, the conformations of the two Solar Flares regions
in the DSH model (LCAT binding domains of apoA-I) are not
identical raising the possibility that only one site for binding
LCAT in nHDL is functional, a fact that can impact nHDL
maturation. For example, the discoidal models create a barrier for
FC diffusion as the protein ring separates the lipid phase into two
disjoint lipid surfaces and impedes the diffusion of FC from one
surface to another. On the other hand, the DSHmodel presents a
continuous lipid surface due to the open conformation of apoA-
I and the micellar-lamellar arrangement of the lipid phase, thus
allowing free diffusion of FC, which can be esterified at a single
functional LCAT binding site.
Jones et al. noted that the DSH model couldn’t accommodate
a FRET geometry constraint between residues 40 and 240 of
apoA-I because the apoA-I termini are far apart due to its spiral
conformation. While this is true in the DSH model, Gogonea
et al. argued that the distance constraint between residues 40
and 240 of apoA-I can be accommodated in a SANS model of
nHDL reconstituted with DMPC (∼80 DMPC per apoA-I chain;
Gogonea et al., 2013). While, Jones et al. have not specified the
composition of the nHDL preparations used in their FRET study,
it is possible that the nHDL particles employed by Jones et al. to
differ in lipid composition (and size) from those used to derive
the DSH model.
Low Resolution Structures of nHDL Reconstituted
with DMPC and FC
The SANS with contrast variation experiments reviewed so
far were performed on nHDL particles reconstituted with full
length apoA-I and the more physiologically relevant POPC and
FC. The newly discovered open conformation of apoA-I in
nHDL raised the following question: is the open conformation
of apoA-I a general feature of lipoproteins or is the lipid
identity that determines whether the protein adopts an open
conformation like in the DSHmodel, or a ring conformation like
in discoidal models? To answer this question, SANSwith contrast
variation and isotopic labeling of the protein measurements were
performed on nHDL particles (9.6 nm) reconstituted with full
length apoA-I and DPMC, or DMPC and FC (Gogonea et al.,
2013). The low resolution structures of nHDL/DMPC particles
(Figure 6A, left) and nHDL/DMPC/FC particles (Figure 6C, left)
were found to have open conformation like in nHDL/POPC/FC
particles (Figure 5A, left). The authors concluded that the open
conformation of apoA-I in nHDL is a general structural feature of
these lipoproteins regardless of the type and the amount of lipid
used to reconstitute nHDL.
The size of the nHDL particle reconstituted with DMPC
measured on native gel (ND-PAGE) was 9.6 nm, but the
composition analysis showed that this particle has ∼80 DMPC
molecules per apoA-I chain (Gogonea et al., 2013). The intriguing
“Y-shaped” low resolution structure of apoA-I obtained from
SANS with contrast variation suggests that apoA-I in the
nHDL/DMPC particle forms a large hairpin (Figure 6A, left)
void of lipids (Gogonea et al., 2013). The lipid low resolution
structure of this particle has a compact shape (Figure 6A,
middle) that fits in between the two arms of the “Y-shaped” low
resolution structure of the protein (Figure 6A, right). The open
conformation of apoA-I (Figure 6B, left) in the nHDL/DMPC
particle implies that, like in nHDL/POPC/FC, the lipid phase
is a combination of lamellar and micellar lipid arrangement
(Figure 6B, right). The nHDL/DMPC particle exhibits the same
distinctive structural features as the nHDL/POPC/FC particle,
despite its smaller lipid cargo, that is, the apoA-I double chain
has an open conformation (Figure 6B, left) and mixed lamellar-
micellar lipid phase (Figure 6B, right, the Turtle model).
The different conformations of apoA-I chains in
nHDL/POPC/FC (spiral) and nHDL/DMPC (“Y-shape”)
might be puzzling, but these nHDL particles have different
lipid compositions and different sizes, so the distinct apoA-
I conformations can be attributed to the amount of lipid
each particle carries. A spiral conformation of apoA-I can
accommodate a larger lipid cargo as it has its entire hydrophobic
surface extended and available for interaction with the lipid,
while the “Y-shaped” conformation can accommodate a smaller
lipid cargo because part of protein hydrophobic surface is
void of lipids and remains packed within a hairpin that shields
its hydrophobic surface from interaction with water. The
thermodynamic stability of the larger or smaller nHDL particle is
achieved by balancing interactions between protein and lipids on
one hand, and hydrophobic interactions within folded domains
of the protein, like hairpins, on the other hand.
Gogonea et al. also reported measurements by SANS with
contrast variation and protein isotopic labeling on an nHDL
particle reconstituted with DMPC and FC that has a larger lipid
phase than the nHDL/DMPC particle (Gogonea et al., 2013).
The low resolution structure of the protein in this particle
has again an open conformation and resembles a horseshoe
(Figure 6C, left); the low resolution structure of the lipid
is compact (Figure 6C, middle) and fits within the protein
horseshoe shape (Figure 6C, right). The overall shape of the
nHDL particle reconstituted with DMPC and FC, given by the
combined low resolution structures of the protein and lipid
phase, is ellipsoidal (oblate, Figure 6C, right) and comes the
closest in overall shape to what discoidal models propose for
the structure of nHDL. Still, this nHDL/DMPC/FC particle
exhibits the same distinctive characteristics as nHDL/POPC/FC
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FIGURE 6 | The low resolution structures nHDL reconstituted with DMPC and with DMPC/FC. (A) Left: The low resolution structure of the protein component
of nHDL reconstituted with DMPC. Middle: The low resolution structure of the lipid component of nHDL reconstituted with DMPC. Right: The low resolution structure
of nHDL reconstituted with DMPC as a combination of the low resolution structures of the protein and lipid components of nHDL. (B) Left: the Y-shaped full length
apoA-I dimer in nHDL reconstituted with DMPC proposed by Gogonea et al. (2013). The apoA-I chains shown in cartoon representation and colored with gradient
red/blue, are oriented antiparallel in helix 5 registry. Middle: Superposition of the apoA-I double chain with the low resolution structure of the protein component of
nHDL reconstituted with DMPC obtained by SANS with contrast variation. Right: The Turtle model of nHDL reconstituted with DMPC; the lipid model was built from
160 DMPC molecules in a combined micellar/lamellar phase. The majority of lipids follow a lamellar arrangement while few of them are arranged radially (as in a
micelle) to accommodate the open conformation of apoA-I. (C) Left: The low resolution structure of the protein component of nHDL reconstituted with DMPC and FC.
The SANS shape resembles a horseshoe. Middle: The low resolution structure of the lipid component of nHDL reconstituted with DMPC and FC. Right: The low
resolution structure of nHDL reconstituted with DMPC and FC as a composite of the low resolution structures of the protein and lipid components of nHDL
reconstituted with DMPC and FC. The low resolution structures of the protein and lipid components fit each other like a “key in a lock.”
and nHDL/DMPC, that is, the open conformation of apoA-I
and the mixed lamellar and micellar organization of the lipid
phase.
The nHDL/DMPC/FC particle is similar in lipid composition
to the double belt model of nHDL (diameter = 10 nm). Each
particle contains 160 PL, thus it can be expected that the
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overall shape of the nHDL/DMPC/FC particle, as visualized by
techniques like EM/cryo-EM/AFM, to be oblate as a discoidal
model (Figure 7). On the other hand, these latter visualization
methods cannot distinguish between the protein and the lipid
components of nHDL, so they cannot tell the exact conformation
of the protein in the particle. The shapes of the discoidal model
and the low resolution structure of nHDL/DMPC/FC are shown
in Figure 7 as they would appear in an EM/cryo-EM/AFM
image. Both front view images have round shapes (emphasized
by the circular dotted line circumscribing them, Figures 7A,B,
left), but the protein shape cannot be distinguished within the
particle, i.e., one cannot say whether the protein is a ring or
has an open shape. In addition, Figure 7 shows a hypothetical
rouleau formation (Figures 7A,B right), which was used in many
EM studies as a “proof/confirmation” that nHDL particles are
dicoidal and stack like coins. The rouleau constructs built with
the model (Figure 7A right) and the low resolution (Figure 7B
right) shapes look similar. When the protein and the lipid
are “painted” differently (Figures 7A,B, second line: protein =
orange, lipid = green) as the SANS with contrast variation would
do, then the protein conformation within the particle can be
visualized (Figure 7B, second line). Note that SANSwith contrast
variation “paints” individual components of the lipoprotein by
using different concentrations of D2O in the buffer (vide supra).
An equivalent technique does not exist for EM/cryo-EM/AFM
methods.
Still, it is worth noting that a recent cryo-EM study produced a
“visualization” of the protein component of nHDL by combining
many individual cryo-EM images and processing them through
computer algorithms (Zhang et al., 2011; Zhang and Ren, 2012).
While the authors of this study concluded that their cryo-
EM images are consistent with the discoidal model of nHDL,
their Figure 5 shows that apoA-I is disjoined (not a ring like
in discoidal models). Their image of the protein is similar
to the SANS low resolution structure of nHDL/DMPC/FC.
Nevertheless, while the SANS low resolution structure is a direct
experimental observation, the electron density of the protein
component of apoA-I is “extracted” from the electron density of
the entire particle, as seen in the cryo-EM images, by computer
algorithms (Figure 5 in Zhang and Ren, 2012), and thus does
not correspond to its visualization as an individual entity like in
SANS with contrast variation.
Folding Dynamics and Plasticity of Amphipathic
apoA-I is the Basis for nHDL Discreet Size Variation
One of apoA-I’s most important structural features is its
plasticity, i.e., its ability to “shrink” or “extend” and bind lipid
cargos in discreet sizes. The feature is critical for the formation of
nHDL and the continuous remodeling of the lipoprotein during
its lifetime as it progresses along the RCT pathway. While the
feature was early recognized, the detailed molecular mechanism
by which apoA-I transits from one HDL size to another is still
debated (Brouillette and Anantharamaiah, 1995; Li et al., 2004;
Gogonea et al., 2013).
In the mid-nineties, when the picket fence model of nHDL
grew in acceptance, it was suggested that apoA-I transits from one
HDL discreet size to the next by adjusting the number of 11 or 22
amphipathic repeats in the “fence” it makes at the periphery of the
lipid phase (Brouillette and Anantharamaiah, 1995). When the
lipid core is small, the repeats left out of the “fence” self-associate
in smaller bundles to mutually shield their hydrophobic surface
from exposure to water. This mechanism is supported by the
observation that two amphipathic repeats are required for fence
extension to incrementally increase the size of nHDL (Brouillette
et al., 1984; Jonas et al., 1989).
At the same time, immuno-reactivity investigations of apoA-
I conformational changes in nHDL of various sizes with
variable cholesterol content pointed to a central region of apoA-
I, P99–P143, which responds to lipid phase enlargement by
significantly altering antibody binding to the Nt and the central
region, i.e., the expansion of the PL phase strengthens antibody
binding competition to adjacent apoA-I epitopes. This result was
understood as evidence that lipids bind to apoA-I domain P99–
P121 in larger nHDL particles (Collet et al., 1991; Marcel et al.,
1991; Calabresi et al., 1993; Bergeron et al., 1995). On the other
hand, the increase in cholesterol content changes the antibody
binding capacity to only two central epitopes, P99–Q132 and
K118–M148, and the Nt epitope E2–W8. This effect of cholesterol
presence on apoA-I central region was later confirmed by
SANS with contrast variation experiments, which showed that
the large hairpin formed in the central region of apoA-I in
nHDL/DMPC (Figure 6A, left) opens up when cholesterol is
present (Figure 6C, left; Gogonea et al., 2013).
A decade later, when the double belt model replaced the
picket fence model as the preferred way to describe the structure
of nHDL, the mechanism for HDL incremental expansion was
redefined by taking into consideration that the Nt mutant of
apoA-I (143–apoA-I) was the structural basis for the double
belt model. Li et al. proposed that nHDL particles larger than
9.6 nm form when the apoA-I double chain ring expands by
incorporating segments from the lipid-free Nt (Li et al., 2004),
while HDL particles smaller than 9.6 nm form when the apoA-
I ring contorts into an out of plane conformation, still binding
to lipid along its entire perimeter (i.e., helices h1–h10; Gu et al.,
2010).
The observation of the low resolution structure of
nHDL/DMPC obtained from SANS with contrast variation
(Figure 6A, left; Gogonea et al., 2013) invited a reassertion of
the nHDL expansion mechanism. The fact that the Turtle model
of nHDL (Figure 6A, right) contains a large hairpin formed by
lipid free amphipathic repeats of apoA-I argues that full length
apoA-I in a 9.6 nm HDL particle do not bind PLs along its entire
perimeter, unless the lipid cargo is large enough (like in the DSH
model). The Turtle model implies that both the Nt and Ct are
bound to PL while the middle region of apoA-I is lipid free, in
contrast to the model proposed by Li et al., in which Nt is lipid
free, while the central region and Ct of apoA-I bind to lipid (Li
et al., 2004).
The revisited nHDL expansion mechanism (Gogonea et al.,
2013) is similar with the one suggested earlier for the picket
fence model (Brouillette et al., 1984; Jonas et al., 1989) and the
immuno-reactivity studies (Collet et al., 1991; Marcel et al., 1991;
Calabresi et al., 1993; Bergeron et al., 1995), in the sense that
it assumes that the Nt and Ct of apoA-I bind to PL in nHDL
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FIGURE 7 | Shape comparison of the discoidal model and the low resolution structure of nHDL. (A) First line: Left: Front view of the discoidal model. A
circular dotted black line emphasizes the round shape of the particle. Middle: Side view of the discoidal model; the two views show that the overall shape of the model
is a disc. Right: Rouleau formation constructed from several discoidal model shapes stacked as coins. Second line: Left: Front view of the discoidal model in which
the protein is colored orange and the lipid is colored green. Middle: The protein component of the discoidal model is a ring. Right: The lipid phase of the discoidal
model is a bilayer disc. (B) First line: Left: Front view of the low resolution structure of nHDL/DMPC/FC. A circular dotted black line emphasizes the overall round
shape. Middle: Side view of the low resolution structure of nHDL/DMPC/FC; the two views show that the overall shape of the particle is a disc. Right: Rouleau
formation constructed from several low resolution shapes stacked as coins. Second line: Left: Front view of the low resolution structure of nHDL/DMPC/FC in which
the protein is colored orange and the lipid is colored green. Middle: The protein component of nHDL/DMPC/FC, located at the periphery of the lipid, has an open
conformation. Right: The lipid phase of the nHDL/DMPC/FC is not a disc. The lipid is a mixture of lamellar and micellar domains.
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particles with smaller lipid cargos, while the central region of
apoA-I binds PL when the particle expands through a growing
lipid phase.
In conclusion, earlier biophysical (i.e., attenuated total
reflection IR spectroscopy, (Wald et al., 1990b); 13C NMR,
(Sparks et al., 1992a); CD) and theoretical studies (Brasseur
et al., 1990) concluded that apoA-I conformation is different in
nHDL of different sizes, containing two A–I chains (Brouillette
and Anantharamaiah, 1995), an assumption reaffirmed by the
latest SANS with contrast variation experiments (Wu et al., 2009;
Gogonea et al., 2013).
MODELS OF SPHERICAL HDL
The second step in RCT is nHDL maturation, the conversion of
nHDL particles into spherical HDL (sHDL) by plasma enzyme
lecithin cholesteryl acyltransferase (LCAT) that transforms FC
into cholesterol ester (CE) on the surface of nHDL (Zannis et al.,
2006). Cholesterol ester moves from particle’s surface into its
core, and triglycerides (TG) join the sHDL lipid core through
lipid transfer mediated by other plasma enzymes (CETP) and
cell receptors (SR-BI; Zannis et al., 2006). As the lipid core
grows it pushes back PL partially exposing their acyl chains to
solvent and thermodynamically destabilizing the HDL particle,
which recruits additional apoA-I molecules to reduce its exposed
hydrophobic surface (Brouillette and Anantharamaiah, 1995).
In plasma, the pool of sHDL particles is heterogeneous and
contains particles of different sizes (8.8–11 nm) and with various
protein/lipid compositions (Huang et al., 2011). The protein
component of sHDL contains two to seven apoA-I chains (Huang
et al., 2011), while the lipid phase packs variable amounts of CE
and TG with the number of PL greatly diminished compared to
nHDL (20–30 PL per apoA-I chain; Wu et al., 2011).
Conceptual and MD Simulation Models of
sHDL
As with nHDL, the lack of a crystal structure for sHDL
lead researchers to rely on alternative interrogation techniques
into the structure of sHDL [CD, MS-crosslinking (Silva et al.,
2008), HDX-MS (Chetty et al., 2013), SANS (Wu et al., 2011),
EM (Zhang et al., 2011)]. Unlike nHDL, homogeneous sHDL
particles are more difficult to obtain by reconstitution. The
procedure to prepare sHDL particles involves mixing nHDL with
LCAT and low density lipoprotein (LDL; Jonas et al., 1990).
Inspired by the crystal structure of the truncated lipid free apoA-
I (143–apoA-I), Borhani et al. were among the first to propose a
model for an sHDL particle with four apoA-I chains, in which
apoA-I is organized as two intersecting double belts (Borhani
et al., 1997). Silva et al. investigated the structure of sHDL
particles reconstituted with two and three apoA-I chains (Jonas
et al., 1990) by employing MS-crosslinking (Silva et al., 2008),
and discovered that all crosslinks found in nHDL are preserved in
sHDL. The authors concluded that the arrangement of the three
apoA-I chains in sHDLmimics the apoA-I arrangement in nHDL
to some extent, that is, the protein chains are oriented antiparallel
with respect to each other in helix 5 registry. To preserve the
inter-chain interaction surface between the two apoA-I chains
present in the double belt model (Segrest et al., 1999), the authors
proposed that the three apoA-I chains be paired with each other
for half of their length to form a symmetric construct made of
three folded rings coined the Trefoil model (Silva et al., 2008).
Thismodel employs Nt truncated apoA-I (143–apoA-I) and does
not include a model for the lipid phase (Silva et al., 2008). Huang
et al. extended the Trefoil concept to sHDL particles with more
than three apoA-I chains (Huang et al., 2011).
At about the same time Segrest et al. proposed a MD
simulation model of an sHDL particle containing two truncated
apoA-I chains (143–apoA-I). The authors performed shorter all
atom force field MD simulations and longer simulations by using
a coarse-grained force field for a simplified description of the
lipids and protein molecules. The simulation (NPT ensemble)
was performed at 310 K after a temperature jump at 410 K (Catte
et al., 2008). The authors concluded that the protein component
is largely rigid and cholesteryl ester (CE) molecules contribute
to protein’s low mobility. In a second MD simulation study on
sHDL Segrest et al. investigated sHDL particles containing two
or three apoA-I chains and lipid compositions similar to those
found in circulating sHDL (Segrest et al., 2013). The simulation
was carried out at 310 K and 1 atm. Spherical HDL particles with
specific composition were assembled and subjected to 5 and 10
ns simulation, and then to 30 ns of MD-simulated annealing.
The authors found that reconstituted sHDL particles contain
an excess of phospholipids as compared to circulating sHDL
particles, and concluded that models of reconstituted sHDL are
less relevant for describing the properties of circulating sHDL.
Chetty et al. (2013) carried out an HDX-MS study of sHDL
isolated from plasma, and confirmed that apoA-I secondary
structure and overall dynamics/stability in sHDL are similar to
what was found in nHDL (Chetty et al., 2012). In addition, Chetty
et al. identified the domain 115–158 of apoA-I (helix 5) in sHDL
as very dynamic (displays bimodal HDX kinetics) and exhibiting
a helix-to-loop transition on a time scale of minutes, as in nHDL
(Chetty et al., 2012, 2013).
The Low Resolution Structure of sHDL
Low resolution structures of the protein and lipid components of
sHDL reconstituted with three apoA-I chains (Jonas et al., 1990),
obtained from SANSwith contrast variation and isotopic labeling
of the protein, were recently published by Wu et al. (2011), and
are shown in Figure 8A (left and middle panels, respectively),
and the low resolution structure of the sHDL particle is shown
in Figure 8A, right panel, as a composite of the low resolution
structures of the protein and lipid components of sHDL. Wu
et al. investigated three possible architectures of the three apoA-
I chains that can fit within the protein low resolution structure:
the Helical-dimer/Hairpin model (HdHp), the 3 Hairpins model
(3Hp), and the integrated Trimer model (iT) (Wu et al., 2011).
In the HdHp model (Figure 8B, left) the three apoA-I chains
are organized as a combination of an apoA-I dimer with the
chains oriented antiparallel in helix 5 registry as found in
nHDL, and an apoA-I monomer in a hairpin conformation.
The apoA-I dimer is rather contorted with a spiral shape
reminiscent of the DSH model of nHDL, and the helical dimer
and the hairpin monomer interact with each other at specific
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FIGURE 8 | The low resolution structure and models of sHDL. (A) Left: The low resolution structure of the protein component of sHDL obtained from SANS with
contrast variation. Middle: The low resolution structure of the lipid component of sHDL. Right: The low resolution structure of sHDL as a composite of the low
resolution structures of the protein and lipid components of sHDL. (B) Schematic representation of the three apoA-I chains in three hypothetical models of sHDL
proposed by Wu et al. (2011): HdHp, 3Hp, and iT. Tubes colored with gradient red, blue and green are used to represent the protein chains. Left: The HdHp model of
sHDL. Middle: The 3Hp model of sHDL; the locations of Ct of chains A and B are interchanged with respect to the HdHp model. Right: The iT model of sHDL; the
locations of Ct of chains A and C are interchanged with respect to the HdHp model. (C) Left: The HdHp model of the apoA-I trimer in sHDL. The apoA-I chains shown
in cartoon representation are colored with gradient red/blue/gray. The chains in the AB dimer are oriented antiparallel in helix 5 registry. The chain C is folded into a
hairpin and interacts for the AB dimer in specific regions of apoA-I. Right: Superposition of the protein model (HdHp) and the lipid low resolution structure. The authors
have not proposed a model for the lipid component of sHDL.
locations along the apoA-I chain (Wu et al., 2011). In the 3Hp
model (Figure 8B, middle) three apoA-I monomers in contorted
hairpin conformation are arranged to fit the protein low
resolution structure. The iT model (Figure 8B, right) resembles
in spirit to the Trefoil model, but unlike the latter, it has only
one node where the three apoA-I chains with contorted shape
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converge. The iT model is less symmetric than the Trefoil model,
uses full length apoA-I chains, and does not contain protein rings.
The three SANS derived models of sHDL (HdHp, 3Hp, iT)
fit well the protein low resolution structure (Wu et al., 2011),
thus to discriminate among them and find the best candidate
for the structure of sHDL, Wu et al. used MS-crosslinking (Wu
et al., 2011). The authors found that only the HdHp model
(Figure 8C) satisfies all 23 crosslinks reported by Silva et al.
(2008) for sHDL and concluded that the protein component of
sHDL is a combination of a spiral dimer and a hairpin monomer.
Based on this model of sHDL, Wu et al. suggested that
a thermodynamically stable sHDL forms during maturation
when an apoA-I monomer in plasma joins a thermodynamically
destabilized sHDL particle with a growing CE core and increased
lipid hydrophobic surface exposed to solvent. This contrast with
the significant entropy barrier one would anticipate forming a
trefoil configuration from a double belt apoA-I and an apoA-I
monomer because the apoA-I dimer requires unzipping halfway
as the third apoA-I chain simultaneously anneals with the
unzipped portion to form the two nodes where the three apoA-I
chains join in the Trefoil model.
A chronological perspective of the development of nascent
and spherical HDLmodels is given in Figure 9. The figure lists for
each model the particle composition and various experimental
techniques used to derive or confirm the model.
CHANGES IN apoA-I STRUCTURE ALTER
HDL FUNCTIONALITY
Numerous structural and functional studies of HDL role in
reverse cholesterol transport (RCT) demonstrated that apoA-I
is not only a scaffold for lipids that gives structural integrity
to HDL particles, but it also provides a functional interaction
interface for various plasma enzymes [e.g., lecithin cholesteryl
acyltransferase (LCAT), myeloperoxidase (MPO), paraoxonase
1 (PON1), cholesteryl ester transfer protein (CETP)] and cell
receptors (e.g., the ABCA1, ABCG1, and SR-BI) encountered
along the RCT pathway. In other words, cell receptors and plasma
enzymes use various epitopes of apoA-I to bind HDL and modify
its lipid cargo.
Amino acid substitutions and deletions were extensively
used to enrich our knowledge of apoA-I conformation and
to better understand structural features of particular domains
of the protein (Bruhn and Stoffel, 1991; Minnich et al.,
1992; Sorci-Thomas et al., 1993; Ji and Jonas, 1995; Schmidt
et al., 1995; Sorci-Thomas and Thomas, 2002). Many naturally
occurring and bioengineered mutations (Table 2; Brouillette
and Anantharamaiah, 1995; Sorci-Thomas and Thomas, 2002)
and posttranslational modifications (Smith, 2010; Rosenson
et al., 2016) in apoA-I have been reported and shown to alter
HDL function or make it dysfunctional (e.g., by chlorination,
oxidation, or nitration of specific apoA-I residues), resulting
in impaired cholesterol eﬄux, change in HDL phenotype, and
increased risk of coronary artery disease (CAD; Rosenson et al.,
2016). Therefore, new diagnostic and therapeutic tactics to
treat cardiovascular disease (CVD) might emerge from a better
understanding of the structural aspects of dysfunctional HDL.
Naturally Occurring and Bioengineered
apoA-I Mutations and their Effect on HDL
Structure and Function
More than 75 naturally occurring and bioengineered mutations
in human apoA-I were reported (Table 2) to induce structural
modifications in lipid free and lipid bound apoA-I and/or to alter
the HDL phenotype in vivo. Approximately half of mutations
decrease HDL plasma levels and can be grouped into amino acid
substitutions that inhibit LCAT activity to some extent or are
associated with amyloidosis (Sorci-Thomas and Thomas, 2002).
The mutations that lead to LCAT inhibition are mainly located
within repeats 5, 6, and 7 of apoA-I (P121–G186; Sorci-Thomas
et al., 2009), while those responsible for amyloid deposition are
mostly encountered in the Nt of apoA-I (D1–L90). Alteration
of HDL function by mutations suggests that changes in the
tertiary structure of lipid bound apoA-I impacts plasma levels of
HDL.
Amino Acid Substitutions Associated with Hereditary
Amyloidosis
In hereditary amyloidosis insoluble amyloid fibrils form when
apoA-I mutants, like apoA-IIowa (G26R; Nichols et al., 1988;
Das et al., 2014) or W50R (Booth et al., 1995; Das et al.,
2014) aggregate, or when proteolytic cleaved fragments (D1–R83)
progressively accumulate, leading to organ failure and death.
Mutants of apoA-I associated with hereditary amyloidosis and
low HDL plasma levels are listed in Table 2 with underlined
font.
Amino Acid Substitutions that Inactivate LCAT
Naturally occurring amino acid substitutions in human apoA-I
associated with low HDL levels and diminished LCAT catalytic
efficiency have been reviewed extensively (Sorci-Thomas and
Thomas, 2002; Kunnen and van Eck, 2012; Schaefer et al.,
2014; Saeedi et al., 2015). Numerous mutation/deletion studies
identified the apoA-I domains that are critical for LCAT
interaction with HDL (Cho et al., 2001; Sorci-Thomas and
Thomas, 2002; Alexander et al., 2005; Koukos et al., 2007a;
Boes et al., 2009; Sorci-Thomas et al., 2009; Roshan et al., 2011;
Fotakis et al., 2013a, 2015). A large body of experimental evidence
suggests that structural modifications within repeats 5, 6, and 7 of
apoA-I (P121–G186) alter its conformation preventing LCAT from
binding to HDL or reducing its catalytic efficiency in converting
FC to CE, leading to a decrease in plasma levels of mature HDL
and a disruption in the RCT cycle (Dhoest et al., 1997; Frank
et al., 1998; Sorci-Thomas et al., 1998, 2009; Sviridov et al., 2000;
Roosbeek et al., 2001).
For example, HDL reconstituted with apoA-IOita (V156E) is
similar in size and composition to HDL reconstituted with wild-
type apoA-I, but displays significantly reduced LCAT catalytic
efficiency (Cho and Jonas, 2000). On the other hand, apoA-
ISeattle, which lacks residues E146–R160 from repeat 6, (P143–A164),
forms small HDL particles (7–8 nm) and was linked to bilateral
arcus senilis (Deeb et al., 1991). Analysis of plasma samples
containing ApoA-IMallorca mutant lacking residues P165–A175
from repeat 7 (P165–G186), revealed lower HDL levels, increased
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FIGURE 9 | Historical perspective of the development of various nHDL and sHDL models. The map displays in chronological order various models of nHDL
and sHDL developed in the last four decades. Alongside each model are listed various biophysical methods used to develop a particular model. While some of the
models were not initially developed by incorporating data from all experimental techniques listed, overtime, some of the listed techniques were used to support that
particular model. The low resolution structures obtained from SANS with contrast variation are displayed next to the nHDL and sHDL models derived from them.
Legend: A-I, apolipoprotein A-I; CC, chemical composition analysis; CD, circular dichroism; cryo-EM, cryo electron microscopy; DMPC,
dimyristoyl-phosphatidylcholine; DSC, differential scanning calorimetry; DSL, dynamic light scattering; CE, cholesteryl ester; EM, negative staining electron
microscopy; EPR, electron paramagnetic resonance spectroscopy; FC, free cholesterol; FRET, Förster resonance energy transfer; IR, infrared spectroscopy;
ND-PAGE, non-denaturing PAGE gel electrophoresis; POPC, palmitoyl-oleoyl-phosphatidylcholine; SANS, small angle neutron scattering; SAXS, small angle X-ray
scattering; TFPS, tryptophan fluorescence polarization spectra; UDS, ultraviolet difference spectroscopy; X-linking-MS, crosslinking mass spectrometry.
triglycerides (TG), and decreased CE content (Martin-Campos
et al., 2002). Another mutant, apoA-IFin features a positive charge
motif (R159–R160) as a result of substituting a leucine to an
arginine (L159R); this mutation leads to lower HDL plasma levels
and makes the protein susceptible to hypercatabolism. In apoA-
IZavalla (L159P) the same residue (L159) is replaced by proline
making the mutant less susceptible to proteolytic cleavage (no
fragments detected in vivo), but small unstable HDL particles are
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TABLE 2 | Compilation of naturally occurring and bioengineered mutations in human apoA-Ia.
Mutation Effect on HDL structure and function Mutation Effect on HDL structure and function
P3R, von Eckardstein et al.,
1989
Interferes with the formation of a β-turn in
Nt
R149A, Koukos et al.,
2007b
Reduces LCAT activity
P3H, von Eckardstein et al.,
1989
(apoA-IMunster3C) interferes with the
formation of a β-turn in Nt
R149V, Sviridov et al., 2000 Does not affect α-helical structure, reduces
LCAT activity
P4R, von Eckardstein et al.,
1989
(apoA-IMunster3B) has no known effect on
RCT
R151C, Daum et al., 1999a (apoA-IParis) inhibits LCAT activation, reduces
HDL levels
R10L, Ladias et al., 1990 (apoA-IBaltimore) has no known effect on
HDL phenotype
R153P, Esperoìn et al., 2008 (apoA-IMontevideo) lowers HDL levels and is
associated with CAD
D13Y, Takada et al., 1991 (apoA-IYame) has no known effect on HDL
phenotype
V156E, Huang et al., 1998 (apoA-IOita) decreases the levels of HDL in
plasma and inhibits LCAT activation
Q17P+FS
cX26, Pisciotta
et al., 2008
Frame shift (FS) and stop codon (X) lowers
HDL plasma levels
A158E, Mahley et al., 1984 (apoA-IMunster2B) is associated with low levels
of HDL in plasma
G26R, Nichols et al., 1988 Initiates deposition of mutant proteins or
proteolytic cleaved fragments
L159R, Miettinen et al., 1997 (apoA-IFin) is associated with low levels of HDL
in plasma
A37T, Matsunaga et al.,
1991
Does not create apoA-I deficiency L159P, Miller et al., 1998 (apoA-IZavalla) is associated with low levels of
HDL in plasma and premature CAD
W50R, Booth et al., 1995 Causes hereditary amyloidosis R160L, Daum et al., 1999b (apoA-IOslo) is associated with low levels of
HDL in plasma and LCAT inhibition
S52C, Zhu et al., 2005 Has no known effect on HDL phenotype H162Q, Moriyama et al.,
1996a; Hoang et al., 2003
(apoA-IKurume) does not produce accelerated
atherosclerosis, reduces LCAT activity
L60R, Soutar et al., 1992 Causes autosomal dominant amyloidosis H162–A207
c; 1K208–Q243,
Moriyama et al., 1996b
Leads to low apoA-I and HDL levels and
bilateral xanthomas of the Achilles tendon,
elbow, knee joint, and corneal opacities
1L60–F71
b; ins V,T, Booth
et al., 1996
Causes hereditary hepatic and systemic
amyloidosis
P165R, von Eckardstein
et al., 1989
is associated with lower apoA-I and HDL levels
1E70–W72, Persey et al.,
1998
Causes hereditary nephropathic systemic
amyloidosis
1P165–A175,
Martin-Campos et al., 2002
(ApoA-IMallorca) impairs LCAT activation and
induces dominant familial
hypoalphalipoproteinemia
N74C, Zhu et al., 2005 Slightly lowers cholesterol efflux Y166F, Wu et al., 2007 Impairs LCAT activity
D89E, von Eckardstein
et al., 1990
Mutation in less conserved domain of
apoA-I, has no known effect on RCT
E169Q, von Eckardstein
et al., 1990
Effect on HDL phenotype is unknown
L90P, Asl et al., 1999a Causes hereditary amyloid cardiopathy R173P, Asl et al., 1999b Is associated with cardiac and cutaneous
amyloidosis
A95D, Araki et al., 1994 (apoA-IHita) does not affect HDL
phenotype
R173C, Weisgraber et al.,
1980
(apoA-IMilano) is associated with reduced
plasma levels of HDL and elevated TG levels
Y100H, Moriyama et al.,
1996a
Does not accelerate atherosclerosis R177H, Assmann et al.,
1993
Effect on HDL phenotype is unknown
D103N, Menzel et al., 1982 (apoA-IMunster3A ) effect on HDL
phenotype is not known
L178H, Petrlova et al., 2012 Leads to altered conformation, decreased
stability, reduced lipid binding capacity, forms
fibrils
1K107, Amarzguioui et al.,
1998
(apoA-IMunster2A ) leads to extensive
intimal amyloid deposits
L178P, Hovingh et al., 2004 Lowers HDL levels, leads to endothelial
dysfunction, increased arterial wall thickness,
CAD
1K107, Rall et al., 1984 (apoA-IMarburg) inhibits LCAT activation 1E191–P220, Nagao et al.,
2014
Is associated with defective lipid binding and
lower HDL levels
K107C, Zhu et al., 2005 Increases cholesterol efflux K195C, Zhu et al., 2005 Reduces lipid binding capability and impaires
cholesterol efflux
K107M, von Eckardstein
et al., 1990
Effect on HDL phenotype not known E198K, Assmann et al.,
1993
(apoA-IMunster4) effect on HDL phenotype is
unknown
W108R, Araki et al., 1994 (apoA-ITsushima) does not affect HDL
phenotype
L203–F229
c; 1L230–Q243,
Funke et al., 1991
Causes HDL deficiency, partial LCAT inhibition,
and corneal opacity
E110K, Takada et al., 1990;
Hoang et al., 2003
(apoA-IFukuoka) does not affect HDL
phenotype, reduces LCAT activity
D213G, Mahley et al., 1984 (apoA-IMunster3D) effect on HDL phenotype is
not know
G129C, Zhu et al., 2005 Increases structural stability, reduces lipid
binding capability, slightly lowers
cholesterol efflux
L218A, Fotakis et al., 2013b Is associated with decrease in plasma
cholesterol and apoA-I levels
E136K, Mahley et al., 1984 (apoA-INorway) effect on HDL phenotype is
not known
L219A, Fotakis et al., 2013b Is associated with decrease in plasma
cholesterol and apoA-I levels
(Continued)
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TABLE 2 | Continued
Mutation Effect on HDL structure and function Mutation Effect on HDL structure and function
E136X, Dastani et al., 2006 Produces circulating HDL deficiency V221A, Fotakis et al., 2013b Is associated with decrease in plasma
cholesterol and apoA-I levels
E139G, Assmann et al.,
1993
Effect on HDL phenotype is not known L222A, Fotakis et al., 2013b Is associated with decrease in plasma
cholesterol and apoA-I levels
1R140–D150, Sviridov et al.,
2000
Affects α-helical structure, reduces LCAT
activation
E223A, Fotakis et al., 2013b Is associated with alterations in HDL phenotype
R140–D150
Q63–D73,Sviridov et al.,
2000
Does not affect α-helical structure,
reduces LCAT activation
1E223–Q243, Fotakis et al.,
2013b
Leads to critical loss of lipid binding and low
HDL levels
L141R, Miccoli et al., 1997 (apoA-IPisa) influences efflux of cholesterol
into plasma and interferes with the
formation of HDL
F225A, Fotakis et al., 2013a Is associated with decrease in plasma
cholesterol, HDL, and apoA-I levels
P143R, Assmann et al.,
1993
(apoA-IGiessen) effect on HDL phenotype
is not known
K226A, Fotakis et al., 2013b Is associated with alterations in HDL phenotype
P143A, Sviridov et al., 2000 Affects α-helical structure, reduces LCAT
activation
V227A, Fotakis et al., 2013a Decreases plasma cholesterol, HDL and apoA-I
levels
L144R, Recalde et al., 2001 apoA-IZaragoza decreases the levels of
HDL in plasma, HDL has more TG and
less CE
F229A, Fotakis et al., 2013a Decreases plasma cholesterol, HDL and apoA-I
levels
L144P, Recalde et al., 1998 Decreases the levels of HDL in plasma,
has no effect on CVD
L230A, Fotakis et al., 2013a Decreases plasma cholesterol, HDL and apoA-I
levels
1E146–R160, Deeb et al.,
1991
Leads to plasma apoA-I and HDL
cholesterol below 15% of normal levels
1E235, Han et al., 1999 (apoA-INichinan) is associated with decreased
protein stability and low plasma HDL levels
E147V, von Eckardstein
et al., 1990
Effect on HDL phenotype is not known
a ApoA-I mutations associated with hereditary amyloidosis (underline font), mutations associated with low HDL plasma levels and LCAT deficiency (italic font) and mutations with
unknown effect (normal font).
b Deletion.
c Frame shift.
produced, presumably due to the extra kink that the additional
proline creates. However, none of these mutants (apoA-IFin and
apoA-IZavalla) were associated with CAD (Miettinen et al., 1997).
ApoA-IMilano has an arginine substituted with a cysteine
(R173C) within repeat 7 (P165–G186; Weisgraber et al., 1980),
which allows apoA-I dimers to covalently link through disulfide
bonds. The large proportion of HDL particles having apoA-
I chains locked through a disulfide bond contributes to the
observed restricted HDL size, lower HDL plasma levels, and
impaired LCAT activity reported for apoA-IMilano(Calabresi
et al., 1994; Sirtori et al., 2001; Nissen et al., 2003; Bhat
et al., 2010). These effects on HDL phenotype should increase
the risk for atherosclerosis (Sirtori et al., 2001), but actually
atherosclerotic lesions in patients with CAD regressed when
apoA-IMilano was administered intravenously (Nissen et al.,
2003). Because the apoA-IMilano chains align in helix 7
registry rather than helix 5 registry (as wild type apoA-I
does), it was suggested that apoA-IMilano adopts a different
conformation in HDL than regular apoA-I does (Calabresi
et al., 1994), however, MD simulations concluded that apoA-
IMilano dimers retain the double belt conformation of wild
type apoA-I in nHDL (Klon et al., 2000) except for Nt and
Ct that buckle around the lipid instead of folding back to
the protein central domain (Bhat et al., 2010). Similarly to
apoA-IMilano, apoA-IParis (R151C, in repeat 5, P143–A164) forms
homodimers that restrict apoA-I mobility and probably alters
its conformation, nonetheless this mutant does not seem to
alter HDL phenotype (Daum et al., 1999a). Finally, in a study
employing an apoA-I double mutant, charged amino acids
were substituted with non-polar ones (R160V/H162A) leading
to loss in LCAT catalytic activity similar to single mutations
R160L and H162Q, however the double mutant protein has not
acquired a significant change in secondary structure or lipid
binding properties as the single mutants (Gorshkova et al.,
2006).
Other Mutations in apoA-I
Several mutations in apoA-I Ct were investigated because this
domain of apoA-I plays a key role in the initial steps of apoA-I
lipidation (Chroni et al., 2003; Kono et al., 2010; Fotakis et al.,
2013a,b; Nagao et al., 2014). For example, Fotakis et al. showed
that apoA-I mutants F225A/V227A/F229A/L230A inhibit HDL
formation in mice (Fotakis et al., 2013b), while Kono et al.
reported that apoA-INichinan mutant (single amino acid deletion,
1E235) has reduced lipid clearance capability (Kono et al.,
2010). In another study, Jayaraman et al. showed that an apoA-
I mutant, in which all four tryptophan residues are replaced
by phenylalanine, 4WF, significantly reduces ABCA1 mediated
cholesterol eﬄux (Jayaraman et al., 2011a). Chroni et al. reported
a similar effect following the deletion of the P220–S231 region,
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while no change in HDL phenotype was observed when A232–
Q243 domain was deleted (Chroni et al., 2003).
Effects of apoA-I Posttranslational
Modifications on RCT
Posttranslational modifications (PTM) of apoA-I (chlorination,
oxidation, nitration, carbamylation, etc.) make HDL
dysfunctional, and there is a large and growing body of
clinical and functional studies suggesting that dysfunctional
HDL is directly associated with atherosclerosis and CVD
progression (Fisher et al., 2012). For example, Shao et al. showed
that the modification of apoA-I lysines by aldehydes (acrolein
and malondialdehyde) inhibits cholesterol eﬄux mediated by
ABCA1 (Shao et al., 2005a, 2010). On the other hand, several
research labs identified MPO as a major enzymatic factor that
chemically modifies apoA-I into various oxidized forms (e.g.,
chloro-, bromo-, oxy-, nitro-, nitrile-, carbamyl-, etc.) that are
abundant in atherosclerotic lesions and detectable in plasma of
CAD patients (Heinecke, 2003; Pennathur et al., 2004; Zheng
et al., 2004; Nicholls et al., 2005; Undurti et al., 2009; Shao et al.,
2012). For example, site-specific chlorination of tyrosine (Peng
et al., 2005; Shao et al., 2005b; Zheng et al., 2005; Wu et al., 2007;
DiDonato et al., 2014) and site-specific tryptophan oxidation
(TrpOx72 -apoA-I, Huang et al., 2014) are instances of apoA-I PTMs
that impair ABCA1-mediated cholesterol eﬄux and reduce
LCAT activity.
Another apoA-I PTM, detected in plasma samples of patients
with type-1 diabetes, which reduces LCAT catalytic efficiency
and disrupts cholesterol transport, is methionine oxidation (Shao
et al., 2006, 2008; Brock et al., 2008). It is interesting to note
that oxidized methionine residues alter the conformation of
Nt and Ct when apoA-I is either lipid free or lipid-bound,
and limited proteolysis experiments suggest that, following
methionine oxidation, the Nt becomes highly solvent accessible
and the posttranslational modified lipid-bound apoA-I is cleaved
at Y192 (Ji and Jonas, 1995; Roberts et al., 1997; Calabresi
et al., 2001). Another PTM of apoA-I detected in atherosclerotic
plaque, that reduces the capacity of lipid bound apoA-I to activate
LCAT, is the MPO-mediated nitration of tyrosine at Tyr166 (Peng
et al., 2005; Zheng et al., 2005; Wu et al., 2007; DiDonato et al.,
2014). DiDonato et al. showed that the mutant TyrNO2166 -apoA-I
reduces the capacity of lipid bound apoA-I to activate LCAT in
vitro, however, the impact on HDL phenotype in vivo is not yet
understood (DiDonato et al., 2014).
In conclusion, PTMs of apoA-I resulting from HDL
interaction with several biological agents (either metabolites or
enzymes) diminish apoA-I’s ability to exchange between lipid-
free/lipid-poor and lipid-bound (HDL) states, a critical feature
indispensable for its participation in the RCT cycle (Cavigiolio
et al., 2010; DiDonato et al., 2013).
RESTORING HDL FUNCTIONALITY
Research carried out over the last decade indicates that the
effects of HDL dysfunction can be ameliorated to some extent
by therapies with statins and niacin, drugs that can restore the
activity of some functional facets of dysfunctional HDL (Lüscher
et al., 2014; Rosenson et al., 2016). This section briefly reviews
some of the many clinical studies carried out so far to test the
effects of several drugs on HDL phenotype and RCT overall.
Khera et al. reported that plasma from patients undergoing
statin therapy can recover cholesterol eﬄux from macrophages
(Khera et al., 2011; Miyamoto-Sasaki et al., 2013), for example,
plasma from patients with type IIb hyperlipoproteinaemia
treated with atorvastatin elevates cholesterol eﬄux from Fu5AH
hepatoma cells (Guerin et al., 2002). Similarly, plasma from
dyslipidaemic patients given pitavastatin, increases the eﬄux
of cholesterol from THP-1 macrophages, the PL content of
HDL, and the activity of PON1 enzyme (Miyamoto-Sasaki
et al., 2013). As a mechanism of action it was suggested that
statins might interfere with ABCA1-mediated cholesterol eﬄux
pathways (Niesor et al., 2015).
The effect of niacin on various HDL functions was reported to
be uneven, but it was found to elevate HDL plasma levels and
reduce TGs. For example, niacin therapy promotes cholesterol
eﬄux from THP-1 macrophages treated with serum HDL (Yvan-
Charvet et al., 2010), but has no effect in statin-treated patients
(Khera et al., 2013). In another study, niacin therapy in patients
with type 2 diabetes restored HDL capacity to increase nitric
oxide production, facilitate endothelial healing, and decrease
oxidative stress (Sorrentino et al., 2010).
Another category of drugs used for restoring the physiological
functions of dysfunctional HDL is that of inhibitors of cholesteryl
ester transfer protein (CETP). Clinical studies revealed that CETP
inhibitors can be effective in increasing HDL plasma levels, but
questions about their toxicity and success in restoring HDL
function linger. For example, torcetrapib was found to have high
toxicity (Barter et al., 2007), however its use in patients treated
with atorvastatin enhances cholesterol eﬄux along pathways
involving the SCARB1 and ABCG1 receptors (Catalano et al.,
2009). On the other hand, a trial using dalcetrapib, a drug that
modestly elevates HDL plasma levels, was discontinued for lack
of progress in patients with acute coronary syndrome (ACS;
Ballantyne et al., 2012), so researchers concluded that dalcetrapib
has either an insignificant effect on restoring HDL function or
more dysfunctional HDL is produced during treatment. Newer
CETP inhibitors that increase the levels of plasma HDL and
reduce plasma LDL significantly are anacetrapib and evacetrapib
(Cannon et al., 2010; Nicholls et al., 2011), but their efficacy in
remedying HDL function awaits extensive trials.
CONCLUSION
This review on recent progress on lipid free apoA-I and HDL
structure and function focuses on theoretical models of lipid free
apoA-I, on one hand, and models of HDL derived from SANS
with contrast variation, on the other hand. This presentation
was motivated by the need to complement recent reviews of
the field that overlook the low resolution structures of nHDL
and sHDL obtained from SANS with contrast variation. The
latter approach has numerous advantageous features: e.g., is
non-perturbing due to the use of neutrons with low energy,
can visualize the protein and lipid shapes separately by using
the contrast variation technique, and captures the average
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conformation of the particle in solution. While the jury is out
there on which models of nHDL and sHDL best describe the
structural features of these lipoproteins, the SANS with contrast
variation measurements performed on nHDL and sHDL are
direct experimental observations and the only direct visualization
of these particles at a resolution of 15–20 Å.
In addition to early and more recent structural data on lipid
free and lipid bound apoA-I, this review discusses many naturally
occurring and bioengineered mutations, and PTMs of apoA-I
and their impact on the structure and the function of HDL.
Finally, recent progress in the use of drug therapy for restoring
the physiological functions of dysfunctional HDL was briefly
recounted.
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